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ABSTRACT 
 
 Low backache (Lumbago) is one of the most common illness  faced by most 
of the people in their day to day life. It’s etiology varies widely like heavy weight 
lifting, long travelling, adapting in appropriate postures, vertebro spinal injury, age 
related degenerative changes etc. Low back pain which is the chief complaint of 
Thandaga Vatham is mentioned in Siddha text book Yugi Vaidhya Cinthamani-800. 
The clinical features of Lumbar spondylosis has become a major problem in day 
today life, despite of many advances in treatment.  Conventional medicines and 
surgical treatments end up with side effects and leave with defect and detriment like 
recurrence of pain, disability & nerve root damage. 
 
 This study is concerned with ‘A Prospective open labeled randomised  
Clinical trial on Thandaga Vatham with Vaeppam pattai Kudineer’ medicine 
evidence is  described in Gunapadam Mooligai Vaguppu Part-I text book. Totally 40 
patients with Thandaga Vatham (20 In patients, 20 Out patients of both sex) were 
selected randomly from OPD of Pothu Maruthuvam, Govt. Siddha Medical College, 
Tirunelveli, Tamil Nadu. They were given  Vaeppam pattai Kudineer 50ml twice a 
day for 30 days.  After the course of treatment majority of cases showed good 
response which is statistically significant. 
 
Keywords:  
Thandaga Vatham, Lumbar Spondolysis, Vaeppam Pattai Kudineer, Cardinal 
Signs, Range of motion, Back Pain Functional Scale Score (BPFSS). 
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CHAPTER-I 
 
INTRODUCTION 
 
 
 Siddha system is one of the ancient system of medicine flourished in southern 
part of India. It helps to lead our day to life under the influence of traditional culture 
and disciplined food habits for healthy living. Siddha system provides ways of curing 
many chronic diseases like auto immune diseases and non communicable diseases.
  
 According to the basic concept of siddha system, man is viewed as a micro 
cosm and the universe as a macro cosm. Principles present in macro cosm can be find 
in micro cosm and vice versa. In other words, man is a miniature of universe.  The 
universe in turn is constituted of five primordial elements (i.e.,) earth, water, fire, air 
and space, it is called Panchabootha Pancheekaranam. 
 
 These five elements, five combinations possess two properties viz., subtle 
(sookumam) and gross (sthoolam). These elements always act in mutual co-ordination 
and can never act independently.  The various proportions in which they combine give 
rise to different substances.  Thus, this theory proposes that 96 basic factors 
(Thathuvangal) exist, which is the basic concept underlying this holistic medical 
science. 
 
 The human body formed by these 96 basic factors is conditioned mainly by: 
 
1) Uyir thathukkal (also called Trithodam or Mukkutram) are the three vital 
humours, viz., Vatham, Pitham and Kapham. 
2) Udal thathukkal are the seven physical constituents. 
 
The foretold 96 factors are the physical, physiological, psychological, 
intellectual aspects of every human. The five primordial elements manifest 
themselves as a human with these 96 basic factors. 
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‘cUnghUs; jhq;FKlY KapUk; 
clw;fhjhu nkhd; gQ;rg+jg; 
gQ;rPfuzg; ghd;ikah nkdTk; 
capHf;fhjhu KapHj;jhnjdTk; 
Kg;gphpthfp Kf;FzkZfp 
cliyAKapiuA Nkhk;gpf;fhj;J 
tUnkd KJkiwtFf;Fe; JzpNg” 
- Neha; ehly; Neha; Kjy; ehly;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
  (ghfk;-I, gf;fk; vz;.78) 
 
The theme of the Siddha system is to place the three humours in equilibrium. 
 
According to Kuthambai Siddhar in his poem, 
 
‘Kg;gpzpjid mwpahj %lHfs; 
vg;gpzp jPHg; ghub - Fjk;gha; 
vg;gpzp jPHg;ghub 
ehbnahUgJ ed;fha wpe;jpby; 
XbtpLk; gpzpNa - Fjk;gha; 
XbtpLk; gpzpNa 
Rj;j tif jhJ jd;idawpe;NjhH 
Rj;j itj;jpaNd - Fjk;gha; 
Rj;j itj;jpaNd 
thAnthU gj;Jk; tha;e;j epiyfz;NlhH 
MAs; mwpthdb - Fjk;gha; 
MAs; mwpthdb” 
 
Drugs are classified based on (i) Source of origin, Eg. Thavaram (Plants), 
Thathu (Metals and Minerals) and Jeeva Products (Animal Products), (ii) Suvai 
(Taste), (iii) Gunam (Character), (iv) Veeriyam (Potency)  (v) Pirivu (Section), and  
(vi) Mode of usage (32 types of internal and 32 types of external medicines). 
 
 We have not touched even the fringe of several esoteric Siddha principles.  
Yet another interesting part of Siddha medicine is the diagnosis by Envagai thervugal. 
 
 
3 
 
So, this study Thandaga Vatham (Lumbar spondylosis), described as a 
degeneration of the Lumbar vertebrae. In India, Lumbar spondylosis affects 60%-80% 
of the adults during some point in their lives. 84% of men and 74% of women are 
suffering from Lumbar spondylosis in the age group of 45-64 years.   
 
Pain in lower back, buttocks, thigh region and it may radiate to foot or toe, 
numbness, tingling feeling throughout one or both legs and burning sensation in the 
hips and legs are the symptoms of Thandaga Vatham which can be correlated in 
modern medicine as Lumbar spondylosis. Details of Thandagavatham is mentioned in 
Yugi Vaidhya Chinthamani-800. It is characterized by body ache, generalised 
weakness all over the body and limbs, yellow coloured stools and yellowish coloured 
urine, incontinence of urine and faeces, constipation followed by diarrhoea, pain in 
the nerves, bones and also in the chest and finally inability to walk. 
 
The clinical trial drug “VAEPPAM PATTAI KUDINEER” is easily 
available and low cost in nature. It is easily available as to compare than other drugs. 
The clinical trial drug Vaeppam Pattai Kudineer has good analgesic,                             
anti-inflammatory activities. It is proven by many pharmacological research works 
undergone on the constituents, thus justify its potential effect in the clinical study of 
the management of Lumbar spondylosis (Thandaga Vatham).   
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CHAPTER-II 
 
AIM AND OBJECTIVES 
 
AIM: 
 
To clinically evaluate the therapeutic efficacy of clinical trial drug in 
Thandaga Vatham. 
 
OBJECTIVES: 
 
Primary Objective: 
• To document the therapeutic efficacy of clinical trial drug in Thandaga 
Vatham. 
Secondary Objective: 
 
• To evaluate the biochemical activity of Vaeppam Pattai Kudineer. 
• To determine the safety profile of clinical trial drugs. 
• To survey the incidence of the disease, according to Age, Occupation, 
Habits, Family History, Paruva Kaalangal, Thinai and Three Vital 
Humours. 
• To evaluate the changes in the Envagai thervugal in Thandaga Vatham 
according to Siddha basic concepts. 
• To evaluate the pharmacological activity of Vaeppam Pattai kudineer. 
• To do a detailed clinical investigations. 
• To collect literary evidence about ‘Thandaga Vatham” disease in 
detail. 
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CHAPTER-III 
 
REVEIW OF LITERATURE 
 
a) SIDDHA ASPECTS: 
 
The concept of Siddha system of medicine is based on 96 Thathuvangal which 
is made up of five primordial basic elements. Among which the three vital humours, 
Aru suvaigal and udal thathukkal play an important role. 
 
The vital humours are Vatham, Pitham and Kapham.  They are also called as 
Uyir Thathukkal or Thiri thathukkal.  They regulate all the physiological activity of 
the human body.   
 
Vatham is characterised by vayu, dryness, pain, flatulence, sensitiveness, 
lightness, air and mind. 
 
Pitham is characterised by gastric juice, bile, energy, heat inflammation, anger 
and irritation. 
 
Kapham  is characterised by feeling of cold, heaviness, running nose, secretion 
of saliva and mucoid discharge in stools and in urine. 
 
When the mutual harmony of the three humours is disturbed, they are called 
Tridosham (or) Mukkutram and they bring about ill health.  This may be due to the 
alteration in the five basic elements and inturn the 96 Thathuvangal. 
 
Vatham has a vital role in locomotion (or) movement activity.  If Vatham is 
disturbed, locomotion is affected. The other two humours are deranged on severity of 
disease. Thus in Noi Naadal and Noi Mudhal Naadal Part-I text book clearly 
explains about Vatham.   
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‘thjkha; gilj;J 
gpj;j td;dpaha; fhj;J 
 rpNyj;Jk rPjkha; Jilj;J” 
- Neha; ehly; ; ;; ;; ; Neha; Kjy; ehly; jpul;L; ; ; ;; ; ; ;; ; ; ;  
   (ghfk;-1 gf;fk; vz;.97) 
 
According to Sivavakiyar, Vatham is Omnipotent. It is the beginning, 
benevolent, soverign, eminent diety.  It has the character to regulate two other 
humours. 
 
 ‘thjkhd NjtNd ahjpahfp epd;wtd; 
 thjkhd NjtNd itafk ikj;jtd; 
 thjkhd NjtNd aWnjhopy; tFj;jtd; 
 thjkhd NjtNd tz;ik fz;L $WNk” 
      - rpt thf;fpaH ehb;;;  
 
The Vatha dosham quoted in various Siddha literature are as follows: 
 
According to Agasthiyar,  
 
‘fhzg;gh thjkPwpy; fhy;iffs; nghUj;J NehTk; 
G+zg;gh Fly; Gul;Lk; kyryk; nghUkpf;fl;Lk;” 
     - mfj;jpaH itj;jpa fhtpak; ; ; ;; ; ;; ; ; 1500 
       (ghly; vz;.10> gf;fk; vz;.2) 
 
According to Theriyar, 
 
‘jf;fthA Nfhgpj;jhy; re;JTise;J jiyNehth 
 kpf;f %hp nfhl;lhtp tpl;lq;nfhpA kyq;fl;Lk; 
 xf;feuk;G jhd;Klq;F KyHe;J tha;eP&wptUk;” 
      - NjiuaH thflk;;;; 
        (ghly; vz;.2> gf;fk; vz;.13) 
 
‘thjtPW md;dkpwq;fhJ fLg;Gz;lhk; tz;zKz;lhk; 
     NkhJfl;LNuhfk; RuKz;lh kpUkYkh Kwq;fhnjd;Wk; 
xJ#hpa thjkdyhF eLf;fKz;lhk; nghUs;fsha;e; 
     jPnjdNt euk;gprpj;J re;Jfs;NjhWk; fLf;Fe; jpdKe;jhNd” 
     - NjiuaH thflk;;;; 
       (ghly; vz;.210> gf;fk; vz;.58) 
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 According to Thirumoolar, 
 
 ‘vwpa ey;thjk; vwpf;Fk; Fzq;NfS 
      Fwpnadf; iffhy; Fisr;R tpyhr; re;J  
 Gwpnad nehe;Jly; gr;irg;Gz; MFNk” 
     - jpU%yH fUf;fpil itj;jpak;; ; ;; ; ;; ; ;-600 
       (ghly; vz;.36> gf;fk; vz;.11) 
 
If Vatham is deranged, the other humours like Pitham and Kapham also gets 
affected. 
thjkpF Fzk;:;;;  
 
‘mwpatpk; %d;wpd; jd;ik nrhd;dhHee;jp 
     Vwpa ey;thj nkwpf;Fq; Fzq;NfS 
Fwpnadf; iffhy; Fisr;R tpyhr;re;J” 
    - jpU%yH fUf;fpil itj;jpak;; ; ;; ; ;; ; ;-600 
 
‘thjtPW md;dkpwq; fhJ fLg;Gz;lhk; tz;zKz;lhk; 
     NkhJfl;F Nuhfk; RuKz;lh kpUkYku Kwq;fhnjd;Wk; 
XJjhpa thjkdyhF eLf;fKz;lhk; nghUs; fsaHe;j 
     jPnjdNt euk;gpj;J re;Jfs; NjhWq; fLf;Fe; jpdKe;jhNd” 
     - NjiuaH thflk;;;; 
       (ghly; vz;.210> gf;fk; vz;.58) 
 
‘jf;fthA Nfhgpj;jhy; re;Jisj;J #iyNehth 
kpf;f nfhl;lhtp tpl;lq; nfhpA kyq;nfl;Lk; 
xf;f euk;Gjhd; Klq;F kyHe;J tha; eP&wptUk; 
kpf;f FspUk; eLf;fkha; Nkdp Fd;wp tUq;fhNd” 
     - NjiuaH thflk;;;; 
     (ghly; vz;.43> gf;fk; vz;.13) 
 
thjk; kpFk; NghJ grpapd;ik> cly; fLg;G> Ruk;> ,Uky;> 
cwf;fkpd;ik> Ruk; eLf;fk;> euk;Gj; jsHr;rp>re;Jfs;NjhWk; Filjy;> ; ; ; ;; ; ; ;; ; ; ;
tpyhr;re;Jfs; Nehjy;>; ; ; ;; ; ; ;; ; ; ;  tapW nghUky;> Flypiwr;ry;> kyr;rpf;fy;> kpFe;j 
nfhl;lhtp Nghd;w FwpFzq;fs; Njhd;Wk;. 
 
According to Yugi Munivar, place of Vatham is below the umbilicus (Pelvic 
plexus): 
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‘ehnkd;w thjj;Jf; fpUg;gplNk Nfsha; 
ehgpf;Ff; fPnod;W etpy yhFk;” 
    - rpj;j kUj;Jthq;f RUf;fk; ; ; ; ; ;; ; ; ; ;; ; ; ; ;  
  (gf;fk; vz;.140) 
 
According to Tamil Maruthuva Sathagam, poem lines 35, 36 is clearly 
mentioned asVatham dwells in Idakalai, Umblical cord, Skin, Joints, Motion, 
Lower abdomen, Hipbones, Nerves, Hair follicles and Muscles. 
 
Further, there are 10 types of Vatham, based on their mode of action and 
location. Vatham is classified into 80 types. 
 
 ‘vd;dNt thje;jhndz;gjhFk; 
  .................................................................” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ;  
        (ghly; vz;.243> gf;fk; vz;.574) 
 
THANDAGA VATHAM is one among Vatha diseases.  
 
THANDAGA VATHAM 
 
SYNONYMS: 
 
 jz;Lthjk;> ,Lg;G thjk; (thj Neha; kUj;Jtk;> gf;fk; vz;.114, 126) 
 
DEFINITION: 
 
 Thandaga Vatham is a condition, characterized by great prostration, in which 
the body is rendered like a log of wood, unable to stretch or fold the limb and pass 
motion or urine.  The whole body assumes rigidity similar to the stiffness appearing 
after death. (T.V. rhk;grptk; gps;is> mfuhjp ghfk;-IV) 
 
AETIOLOGY: 
 Any modification (or) disturbances in the uyir thathus, especially in Vatham 
can result in Vatha diseases. 
The factors that play its role in modification of Vatham are,  
 
1) Environmental factors 
2) Physical factors 
3) Factors of Kanmam 
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1) Environmental factors (Seasonal Variations):  
 
 ‘Mbahjpaha; Ig;grp<wha; 
   Mdpykjw; Nfhuurpay; fhyk;” 
    - rjfehb (Neha; ehly; Neha; Kjy; ehly; ghfk;-I) 
      (gf;fk; vz;.167, 168) 
 
According to Sathaga Naadi the Vatha disease get predominant in the month 
of Aadi to Iypasi (July to November). 
 
‘thj tHj;jid fhyNkNjh ntd;dpy; 
 kUTfpd;w Mdp fw;flfkhFk; 
 Mjitg; grpNahL fhHj;jpif jd;dpy; 
 mUlNk......................................................” 
    - a+fp itj;jpa rpe;jhkzp; ;; ;; ;  
      (ghly; vz;.245> gf;fk; vz;.76) 
 
 In Yugi Vaidhya Chinthamani-800, Vatham is provoked in own site on the 
month of Iypasi and Karthigai (Ntw;W epiy tsHr;rp) and retains normal in the rest 
of the month (jd;dpiy miljy;).  
 
 ‘gJkj;ijg; g+f;f itf;Fk; ghDkpf;f fhAk; 
  KJNtdp ypw;G tpePH Kw;Wk; - fJnkd 
  tw;Wk; fgFk; thAkpFk; .....................................” 
     - kUj;Jt jdpg;ghly;; ; ;; ; ;; ; ; 
 
 Nkw;$wpa ghlypd; %yk; KJNtdpw; fhyj;jpy;> #hpa ntg;gj;jpd; 
fhuzkhf ngUthhpahf ePH Mtpahf;fg;gl;L g+kpapy; twl;rp epyTk;. mJNghy; 
ekJ clypy; twl;rp Vw;gl;L tsp Neha; tUtjw;F fhuzkhfpwJ.  
 
2) Physical factors: 
 
1). According to Sabapathy Manuscript, 
 
 ‘tspjU fha;fpoq;F tiutpyh japyy; Nfhio 
  KspjU Nghd;kpFf;F Kiwapyh tz;b Nfhly; 
  FspHjU tspapw; Njfq;Fspg;Gw Tyty; ngz;bH 
  fspjU kaf;fk; ngw;NwhH fbnray; fUtpahkhy;” 
     - rghgjp ifNaL-rpj;jkUj;Jtk; (nghJ); ; ;; ; ;; ; ;  
       (gf;fk; vz;.624) 
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Excessive intake of rhizomes and certain vegetables can increase Vatha 
diseases.  Irregular food intake, prolonged exposure to cold air, staying prolonged in 
hills area, excessive sexual activity and hereditary factors produce Vatha diseases. 
 
2). According to Noi Naadal and Noi Mudhal Naadal Part-I, text 
 
 ‘GspJtH tpQ;Rq;fwp ahw;g+hpf; Fk;thjk; 
 .................................................................................” 
     - Neha; ehly; Neha; Kjy; ehly;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
       (ghfk;-I, gf;fk; vz;.23) 
 
 Sour and Astringent food stuffs can increases the Vatham. 
 
 ‘khj;jpa Gspg;G kPwpy; te;jpLk; thjkhFk; 
  Nrj;Jke; jz;zPH gpj;je; jP fhw;W thjkhNk” 
     (mfj;jpaH ehb) 
     - Neha; ehly; Neha; Kjy; ehly;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
       (ghfk;-I, gf;fk; vz;.22) 
 
 Intake of large amount of sour food can increases Vatham. 
 ‘thjNk Gspg;G Ntz;Lk; td;gpj;jq; frg;G Ntz;Lk; 
 jPjpyhrp Nyw;gde;jhd; NrHe;jpLk; ,dpg;G Ntz;Lk; 
 Xjpa thj gpj;j rpNyw;gd njhe;jj; NjhHf;Ff;  
 fhjyha;j; JtHj;jy; fhuy; ctHg;NghL fUJq;fhNz” 
      (,uj;jpdr; RUf;f ehb) 
     - Neha; ehly; N; ;; ;; ; eha; Kjy; ehly;; ; ;; ; ;; ; ; 
       (ghfk;-I, gf;fk; vz;.22) 
 
 The sour food definitely increases the Vatham while astringent foods are 
added into it. 
 
3). According to Yugi Muni in Yugi Vaithya Chinthamani-800. 
 
 ‘gfuNt thjkJ Nfhgpj;jg;Ngh 
 gz;ghf ngz;Nghfk; mJjhd; nra;apy; 
 efuNt ntFJ}u top elf;fpy; 
 espuhd fhw;WNk gdpNky; gl;lhy; 
 kpfuNt fha;fs; fdpfpoq;F jd;id  
 kpftUe;jp kPwpNa japHjhd; nfhz;lhy; 
 KfuNt KJnfYk;ig KWf;fp nehe;J 
         Koq;fhYk;> fZf;fhYk; fLg;Gz;lhNk” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
       (ghly; vz;.285, gf;fk; vz;.89) 
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 Excessive sexual activity (or) desire, walking for a long distance, prolong 
exposure to cold extreme dampness, Intake of harmful food stuffs like excessive curd 
consumption after eating fruits, vegetables and tubers produce toxic factors which 
affects muscles and bones produce Vatha diseases. 
 
 ‘vd;dNt thje;jh ndz;gjhFk; 
 ,fj;jpNy kdpjHfSf; nfa;AkhW 
 gpd;dNt ngz;jidNa NrhuQ;nra;J 
 nghpNahHfs; gpuhkziuj; J}lzpj;Jk; 
 td;d Njtr; nrhj;jpy; NrhuQ; nra;J 
 khjh gpjh FUit kwe;j NgHf;Fk; 
 fd;dNt Ntjj;ij epe;ij nra;jhy; 
 fhaj;jpw; fye;JLNk thje;jhNd” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
       (ghly; vz;.243, gf;fk; vz;.76) 
 
 Breach of trust, abusing the pious, elderly people, priests and holy spirits, 
exploitation of charitable properties, ingratitude towards mother, father and teacher 
results in Vatha diseases. 
 
 ‘jhndd;w frg;NghL JtHg;G ifg;G 
 rhjfkha; kpQ;RfpDk; rikj;j tz;zk; 
 Mndd;w MwpdJ Grpj;j yhYk; 
 Mfhaj; NjwyJ Fbj;jyhYk; 
ghndd;w gfYwf;f kpuhtpopg;G 
gl;bdpNa kpfTWjy; ghunka;jy; 
Njndd;w nkhopahH Nkw;rpe;ij ahjy; 
rPf;fpukha; thjkJ nrdpf;Fe;jhNd” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
       (ghly; vz;.244, gf;fk; vz;.76) 
 
 Excessive intake of bitter, astringent and salty foods, intake of dry and old 
cooked rice, drinking polluted rain water, irregular sleep patterns, undue starving, 
excessive weight lifting and sexual perversion can induce Vatha diseases. 
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 ‘Mdhd twd; wd;idNa kjpah khe;jH 
 mfjp guNjrpaH fl; fd;d kPahH 
 Nfhdhd FUnkhopia kwe;jNgHfs; 
 nfhiyfsT ngha;kq; Fwpj;j NgHf;F 
 csdhd rle;jd;dpy; thjk; te;J 
 clw;gtpf;Fk; Ntjj;jp Yz;ik jhNd” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
       (ghly; vz;.253, gf;fk; vz;.95) 
 
Disobedience attitude towards God, refusing food for destitute and Sanyasi, 
disagreeing the advice of preceptors, stealing, unjustice and speaking lie leads to 
Vatha diseases. 
4). According to Theraiyar in Theraiyar Vagadam text,  
 
‘nta;apypy; elf;ifahYk; kpfj; jz;zPH Fbf;ifahYk; 
Nra;apio kfspiur; NrHe;jd gypf;ifahYk; 
igaNd cz;ikahYk; ghfw;fha; jpd;ifahYk; 
ijaNy thjNuhfk; rdpf;F nkd;wwpe;J nfhs;s” 
     - NjiuaH thflk;;;; 
       (ghly; vz;.16, gf;fk; vz;.5) 
 
 Excessive exposure in sunrays, excessive intake of water, excessive sexual 
activity, intake of bitter guard may disturb the normal functions of Vatham. 
5). According to Pararasa Sagaram, 
 
‘njhopy;ngW ifg;Gf; fhHj;jy; JtHj;jy; tpQ;RfpDQ; NrhWk; 
gioajhk; tuF kw;iwg; ige;jpiz aUe;jp dhYk; 
vopy;ngwg; gfY wq;fp ,utpdp ywq;fh jhYk;  
kioepfH Foy dhNs thjq;Nfh gpf;Fq; fhNz” 
 
Improper dietary habits and sleep pattern can cause Vatha diseases. 
 
‘fhyq;fz; khwp Az;Zq; fhhpaj; jhYe; jz;zPH 
rhyNt aUe;jp dhYQ; re;jpap Yl;fhHe;jhYk; 
thythH Kiyey; yhNs thjKw; gtpf;Fq;fhNa” 
      - guuhr Nrfuk;;;; 
Irregular food habits, intake of excessive water, sitting in the cold air at 
evening hours leads to Vatha diseases. 
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‘ghhpdpw; gag;gl;lhYk; gyUld; Nfhgpj;jhYk; 
fhnudf; fUfpNahbf; fOkuj;J uj;jpdhYk;; 
VHngW jdJ neQ;rpd; kpfj;Jf;f kile;jpl;lhYk; 
ghhpa fhw;wpdhYk; glhPDk; thjq;fhZk;” 
      - guuhr Nrfuk;;;; 
 Fear, angry, anxiety, stress, exposure to cool air can cause Vatha diseases. 
 
6). According to Agasthiyar in Agasthiyar Gunavagadam,  
 
‘tptuklh mrjp rd;dp %is NehT  
tphpthd %isaJ kpUJthfp 
mtdpjdpy; jplkhfg; NghtjhYk; 
mg;gNd %j;jpu Fz;bf;fha; tpahjpahYk; 
jtKdptH jPHf;fhf;if Nkf Nuhfk; 
jd;ikAs;s Kj;jz;L nfhbtpahjp 
mtkpyhg; ghpr euk;gOj;jq; fz;lhy; 
mZFklh thjNeha; MFk;ghNu” 
     - mfj;jpaH Fzthflk;; ;; ;; ; 
 Fatigue, Epilepsy, Brain diseases, Renal diseases, Genito urinary diseases, 
Connective tissue disorders induced Vatha diseases. 
c). Factors of Kanmam (Hereditary): 
 In Siddha system many diseases are said to be caused by Kanmam which 
means the deeds committed by an individual in his / her present and previous births. 
 According to Agasthiyar Kanma Kandam-300,  
‘E}nyd;w thjk; te;j tifjhNdJ 
Jz;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
iffhypy; Kof;fpaJ tPf;fkJ 
NfhypNy gLfpd;w tpUl;rkhd  
Foe;ij kue;jid ntl;ly; Nky;Njhy;rPty; 
 
E}ypNy rPt[e;J fhy; Kwpj;jy; 
ey;ynfhk;G jioKwpj;jy; eypj;jy; jhNd” 
     - mfj;jpaH fd;kfhz;lk;; ; ; ;; ; ; ;; ; ; ; 
       (ghly; vz;.56, gf;fk; vz;.23) 
 Vatha Kanma Varalaru says that the psychological factors such as removing 
the bark of living trees, injuring the animals, cutting the branches in the living trees 
and plucking the leaves may produce Vatha diseases. 
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CLINICAL FEATURES: 
 
‘tOj;jNt %yhjhuj;ijg; gw;wpNa 
kUtpNa NkNywp KJFz;lhjy; 
tpOj;jNt rpurpy; te;J tpaHTkhfp 
tpFthf Nehthfp Nkdp fd;dp 
gOj;jNt clk;ngq;Fk; gQ;R Nghyhk; 
ghq;fhd kyry kQ;rshFk; 
FOj;jNt njz;lkhk; thje;jd;idf; 
$wpNdhq; Fznky;yhq; $He;J ghNu 
$He;jpl;l kyryq;fs; Jhpjkhdhy; 
nfhz;llf;fpg; gpd;Gjhd; nfhbjha; js;sp 
CHe;jpl;l rhPuj;jp Yjpu kPwp 
cwj;Nja;j;Jj; jiyajdp nyz;nza; thHf;fpy;  
thHj;jpl;l top elf;fpy; nkj;j te;jhd; 
thje; jhDw;gtpj;J eil nfhlhky; 
ehHe;jpl;l euk;NghL vYk;gpw; #o;e;J 
eZfpNa Nahb neQ;rp NtWe; jhNd” 
     - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
       (ghly; vz;.288,289 gf;fk; vz;.109,110) 
 
Review of Literature described below says the pain in low back area with the 
clinical features more or less correlates with the Thandaga Vatham. 
 
i). According to Dhanvanthri Vaidhyam, 
 
‘Mkfl;ljdhy; thA tjpfkha;r; rpNyw;gdj;ijj;  
jhkfl;lhfr; NrHj;Jj; jbj;jpLQ; rhPunky;yhk; 
Nehkf; fl;lhd Nkdp Etypisg; ngaHg;Gj; Njhd;Wk; 
jhkf; fl;lhd Nuhfe; jz;lf thjkhNk”   
     - jd;te;jphp itj;jpak;; ; ; ;; ; ; ;; ; ; ; 
 
 Vatham is associated with Kapham results in generalised odema, obesity and 
generalised debility in Thandaga Vatham. 
 
ii). According to Roganiga nirnayasaram: 
 
‘Njfk; jz;lj;ij Nghy; tpOe;J mirtpy;yhky; ,Uf;Fk;” 
 
 Body is rendered like a log of wood. 
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iii). According to Jeevaratchamirtham, 
 
thAthdJ vz;nza; t];J> ke;j t];J> rPj tPhpa t];J> japH> mjpf 
ytzk;> gfy; epj;jpiu> gjpdhd;F Ntfq;fis kwpj;jy; Mfpa ,itfspdhy; 
gpwe;j rg;j jhJf;fspYk; tpahgpj;J mitfisf; fiyj;J tpl;L 
Mkhra];jhdj;ij mDrhpj;Jr; rpNy\; gpj;jq;fisj; jd;Dld; NrHj;Jf; 
nfhz;L mtaq;fspd; nraiy khw;wp tpLk;. ,jdhy; urhjp jhJf;fspy; 
kuj;jy; (Numbness)> rPjsk; (Cold)> cs;nshpr;ry; (Burning Sensation)> rhPuq; 
fdj;jy; (Heaviness of body)> Qhgf kwjp (Loss of Memory)> gpuik 
(Psychosis)>mjpf Ntjid (Severe pain)> ePHf;fl;L (Anuria) vd;Dk; 
,f;FwpFzq;fNshL NjfkhdJ jz;lj;ijg; Nghy tpOe;J mirjYk;> 
ePl;lYk; klf;fYk;> vOjYk; ,y;yhjpUf;Fk; (Body is rendered like a log wood 
and unable to flex, extend and rotate). 
  - mDNghf itj;jpa Njtufrpak; ; ;; ;; ;  
(Kjy; ghfk;> gf;fk; vz;.164). 
 
iii). According to Sikitcharatna Deepam: 
 
 thAthdJ %yhjhuj;ijg; gw;wp NkNywp KJfpypUe;J rpurpy; te;J 
tpaHj;J NehAz;lhf;fp rHthq;fj;ijAk; NehAwr; nra;tJld; kyryk; kQ;rs; 
tHzkhfTk;> Njfj;ij jz;lfk; Nghy; ePl;l tplhky; nra;Ak;.  
 
 Excessive sweating all over the body 
 Yellow coloured urine 
 Body is found to be like a log of wood 
 
 ‘,Lg;gJ fLj;J cise;J 
 ,iltplh typj;Jf; nfhs;Sk; 
 KLf;fkha; FdpaNt jhd; 
 KLfpNa epkpu nthl;lhJ 
 JLf;nfd te;J mlUk; 
 RukJ mw;gk; mw;gk; 
 Rlf;nfd ,Lg;igr; Rw;wp 
 rhHe;jpLk; thjk; jhNd..........” 
    - thjNeha; kUj;Jtk;; ; ;; ; ;; ; ; 
      (gf;fk; vz;.114) 
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Here in Idupu Vatham, pain aggrevates while walking and subsides at rest; 
While lying on bed, the patient is unable to move their lower back. 
NkYk;> 
 
‘elg;ngd NghJ nkj;j ea;aNt typf;Fnkd;d 
nflg;ngdNghJk; rw;Nw Fznkd Njhd;Wkhfpy; 
gLg;gd NghJk; ahkk; ghfpahy; thjKz;lhk; 
,Lg;ngd NrUk; thjj;jpaypJ vz;ZtPNu” 
     - thjNeha; kUj;Jtk;; ; ;; ; ;; ; ; 
       (gf;fk; vz;.114) 
NkYk;>  
 
Thandu Vatham, is described in Vatha Noi Maruthuvam has the clinical 
features given below: 
Due to cold food stuffs, day time sleep, in case of Thandu Vatham the patient 
develops increase level of Vatham their by deranging the Pitham and Kapham.  This 
leads to burning sensation (cs; vhpr;ry;), psychosis (gpuik), asthma (,isg;G)and 
severe pain (Ntjid). 
In Thandu Vatham, the low back bone gets inflammed resulting in 
generalised debility, pain, body becomes weaker. 
 
‘jz;L thjj;jpd; Fzj;ij rhw;wf;Nfhsha; klkhapNy 
gz;Nljz;L kpf Cjp gw;wpnghJkp nfhz;bUf;Fk; 
tpz;Nlhk; rpy NghJisTz;lhk; kpFe;j thl;lKz;lhk; 
nfhz;Nl kdKk; jsHr;rpAk; Nfhg kjpfk;fhZnkd;Nw” 
      - thjNeha; kUj;Jtk;; ; ;; ; ;; ; ; 
        (gf;fk; vz;.126) 
Due to the changes in Uyir thathus especially Vatham, the 96 Thathuvangal 
gets affected.  As said above, due to various causes the following changes occurs in 
Thandaga Vatham.  
 
DIAGNOSIS IN SIDDHA: 
 
A). Piniyari Muraigal (Methods of Diagnosis) is based upon three main topic 
namely, 
 
 
17 
 
 Poriyal Aridhal (Physical Examination, Perception) 
 Pulanal Aridhal (Palpation) 
 Vinavudhal (Interrogation) 
 
i). Poriyal Aridhal (Inspection): 
 
 ‘Poriyal Aridhal’ means examining the five sense organs of perception. 
 
 
QhNde;jphpaq;fspd; Ma;T; ; ; ;; ; ; ;; ; ; ;  
Gyd;fs;; ;; ;; ; njhopy;fs;; ;; ;; ; jz;lf thjj;jpy; ghjpg;G; ; ; ;; ; ; ;; ; ; ;  
nrtp xypia mwpa nra;a  ,ay;G 
nka; clypy; Cw;iw mwpjy; KJfpy; typ> tPf;fk; 
fz; xspia mwpar; nra;jy; ,ay;G 
ehf;F Ritia mwpar; nra;jy; ,ay;G 
%f;F thridia Efur; nra;jy; ,ay;G 
  
fd;Nke;jphpaq;fspy; Ma;T; ; ; ; ;; ; ; ; ;; ; ; ; ;  
Gyd;fs;; ;; ;; ; njhopy;fs;; ;; ;; ; jz;lf thjj;jpy; ghjpg;G; ; ; ;; ; ; ;; ; ; ;  
tha; Ngrr; nra;Ak; ,ay;G 
if ,LjYk;> Vw;wYk; nra;Ak; ,ay;G 
fhy; elf;fr; nra;Ak; fhy;fspy; typ elf;fr; rpukk; 
vUtha; kyj;ijf; fopf;Fk; kyr;rpf;fy; 
fUtha; fU> Rf;fpyj;ijf; fopf;Fk; ,ay;G 
  
ii). Pulanal Aridhal (Palpation): 
 
 By examining the pulan i.e., the sense organ of the patient, the physician can 
able to diagnose the disease. 
 
iii). Vinavudhal (Interrogation): 
 
 Vinadhal is questioning and gathering information regarding the previous 
history of disease and clinical features which are much essential for diagnosis. 
B). Envagai Thervugal (Eight Diagnostic Tools): 
 
The excellent and unique diagnostic methods in the Siddha system is the 
Envagai Thervugal. 
 
 ‘ehb ];ghprk; eh epwk; nkhop tpop  
      kyk; %j;jpukpit kUj;JtuhAjk;” 
    - Neha; ehly; Neha; Kjy; ehly;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
      Kjy; ghfk; (gf;fk; vz;.270) 
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1. Naadi (Pulse): 
 
Among the Envagai Thervugal,Naadi is most important. Naadi is felt as 
Vatham, Pitham and Kapham with the tip of the index, middle and ring fingers 
respectively over the lower end of the radius in right side for males and left side for 
females. 
 
Normally Vatham, Pitham and Kapham are held in the ratio of 1:1/2:1/4. 
Derangement in this will reflect as disease. Naadi Nadai in Thandaga Vatham, 
 
‘jpUj;jkhk; thjj; NjhNl jPq;nfhL gpj;jQ; Nrhpy;  
nghUj;J fs;NjhWk; nehe;J NghjNt gpbf;Fk; #iy” 
    - Nehapd; rhuk; ; ;; ;; ; - rpj;jkUj;Jtk; (nghJ); ; ;; ; ;; ; ;  
      (gf;fk; vz;.634) 
‘fhzg;gh thj kPwpy; 
  fhy;iffs; nghUj;J NehFk;” 
    - fhtpaehb - rpj;j kUj;Jtk; (nghJ); ; ;; ; ;; ; ;  
      (gf;fk; vz;.634) 
  
 ‘nrhy;ypa itaj;NjhL gpj;jKq; $bw;whdhy; 
  ty;ypak; Nghyf; Fj;Jk; ike;jNd vYk;G NjhWk;” 
     - fhtpaehb - rpj;j kUj;Jtk; (nghJ); ; ;; ; ;; ; ;  
       (gf;fk; vz;.634) 
 
‘mwpe;JghH thjNk jdpj;jhdjhy;  
  rhpe;jplNt fhy; Klf;Fk;” 
   - mfj;jpaH uj;jpdr; RUf;fk;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
     (gf;fk; vz;.634)  
 
‘thjj;jpy; Nrj;Jkkhfpy; typNahL tPf;fKz;lhk;” 
      - mfj;jpaH ehb;;;  
 
In Thandaga Vatham the following Naadi Nadai are commonly felt. 
 
 Vatham 
 Vatha Pitham 
 Pitha Vatham 
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In Thandaga Vatham,  
2. Sparisam (Sensation to touch): 
 
 Heat, swelling, pain is found in some cases. 
 
3. Naa (Tongue): 
 
 No abnormality is seen in Naa. 
 
4. Niram (Colour): 
 
 Some skin colour changes seen in affected area due to inflammatory 
mechanism. 
 
5. Mozhi (Voice): 
 
 No abnormality is seen. 
 
6. Vizhi (Eyes): 
 
 Eye pallor is reported in some cases. 
 
7. Malam (Faeces): 
 
 Constipation is reported in some cases. 
 
8. Moothiram (Urine): 
 
 In urine, Neerkuri and Neikuri examinations are done. 
 
Neikuri (Oil Examination): 
 
 Prior to the day of urine examination, the patient is instructed to take a 
balanced diet and quantities of food must be proportionate to his / her appetite.  The 
patient should have no disturbed sleep. After waking up in the morning, the first 
voided urine is collected in a clear wide mouthed glass dish or china clay bowl and is 
subjected to analysis of ‘Neerkuri’ and ‘Neikuri’ within one and a half an hour of its 
collection. 
 The collected urine specimen is kept in a glass dish or china clay container and 
observed under direct sunlight without shaking the vessel. Then add one drop of 
gingelly oil and observed the spreading pattern and conclude as follows: 
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‘muntd ePz;bd ‡Nj thjk; 
 MopNghw; gutpd; m‡Nj gpj;jk; 
 Kj;njhj;J epw;fpd; nkhopt njd; fgNk” 
     - Neha; ehly; ghfk;; ; ;; ; ;; ; ;-1 
       (gf;fk; vz;.298, 299) 
Neerkuri: 
 
 ‘te;j ePHf;fhp nail kzk; Eiu vQ;rnyd; 
  iwe;jpaYsit aiwFJ KiwNa” 
     - rpj;j kUj;Jthq;f RUf;fk;; ; ; ; ;; ; ; ; ;; ; ; ; ; 
       (gf;fk; vz;.510) 
 
In urine examination the following characteristic features are observed 
namely. 
 Niram  - Colour 
 Edai  - Specific gravity 
 Manam - Smell 
 Nurai  - Frothy nature 
 Enjal  - Quality of urine voided 
  
 Apart from these, frequency of micturition, abnormal constituents such as 
sugar, protein, blood stains, pus, crystals also to be found out. 
C). Paruvakaalam (Seasonal variations): 
 
Sl. No. State of Kuttram Kaalam 
1. Vatham thannilai 
adaithal 
Munpani Kaalam, Pinpani 
Kaalam, Koothirkaalam, 
Elavenil Kaalam 
2. Vatham thannilai 
valarchi Muthuvenil Kaalam 
3. Vatham vetrunilai 
valarchi Karkaalam 
 
 KJNtdpw; ;;; fhyj;jpy; ekJ clypy; twl;rp Vw;gl;L tspNeha; tUtjw;F ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;
VJthfpwJ. 
 
 
D). jpiz (Geographical distribution): 
 
FwpQ;rp : kiyAk;> kiy rhHe;j gFjpAk;  
Ky;iy : fhLk;> fhL rhHe;j gFjpAk; 
kUjk;  : taYk;> tay; rhHe;j gFjpAk; 
nea;jy; : flYk;> fly; rhHe;j gFjpAk; 
ghiy  : kzYk;> kzy; rhHe;j gFjpAk; 
 
 Ky;iy kw;Wk; nea;jy; epyq;fspy; thj Neha;fs; ngUkstpy; Vw;gLk;.; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ;  
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E). VO cly; jhJf;fspd; Ma;T; ; ; ;; ; ; ;; ; ; ;  (Seven Udal thathukkal Examination):  
 
Sl. 
No. 
Udal 
Thathukkal 
Normal 
Functions Increased conditions 
Decreased 
conditions 
1. Saaram 
Strengthens the 
body and mind. Loss of appetite, 
excessive salivation. 
Tiredness, 
fatigue, 
diminished 
activity of the 
sense organs. 
2. Senneer 
Preserves 
brightness, 
boldness, 
power and 
knowledge. 
Boils and tumours in 
different parts of the 
body, spleenomegaly, 
colic pain, increased 
blood pressure, red eyes 
and skin, Jaundice, 
leprosy, Haematuria. 
Tiredness, 
Lassitude, 
Anemia. 
3. Oon 
Gives structure 
and shape to 
body, 
Represents the 
tissues. 
Tumours or extra 
growth around the neck, 
face, abdomen, thigh, 
genitalia etc., with 
dyspnoea. 
Muscle wasting 
4. Kozhuppu 
Lubricate the 
joints. 
Tumours or extra 
growth around the neck, 
face abdomen, thigh, 
genitalia etc., with 
dyspnoea and loss of 
activity. 
Pain 
5. Enbu 
Physical bone 
structure. Extra growth of bone 
and teeth 
Weak bones, 
teeth, nails and 
hair. 
6. Moolai 
It is present in 
the bones and 
gives strength 
to them. 
Heaviness, swollen 
eyes, swollen 
phalanges, oliguria and 
non-healing ulcers. 
Osteoporotic 
changes. 
7. Sukkilam or Suronitham 
Meant for 
reproduction 
and 
inheritances. 
Increased sexual 
activity and symptoms 
as that of urinary 
calculi. 
Infertility, pain 
in genitalia. 
 
In Thandaga Vatham: 
 Saaram, Seener, Kozhuppu, Enbu thathukkal are commonly affected. 
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Saaram : Weakness, tiredness of body. 
Seener  : Early morning stiffness occurs in affected joints. 
 Kozhuppu : Restricted movements in joints and reduced  
Inter vertebral disc. 
 Enbu  : Produces degeneration in lumbar vertebrae, spondylotic  
changes and extra osteophytic formation 
F). Kf;Fw;wq;fspd; Ma;T; ; ; ; ;; ; ; ; ;; ; ; ; ;  (Mukkutram examination): 
 
Sl. 
No. Vatham Location Function 
In Thandaga 
Vatham 
1. Pranam Chest region Regulate respiration and 
controls the mental 
functions, functions of 
heart, lungs and brain 
Not Affected  
2. Abanam Pelvic region Control excretion such as 
sweating evacuation of 
stools, ejaculation of 
sperms, micturition, 
menstruation and 
parturition. 
May be 
Affected 
3. Viyanan Nose and skull Helps in various 
movements of the body 
and responsible for 
nervous functions and 
sensation 
Affected 
4. Uthanan Thorat Responsible for speech, 
vomiting, hiccough, 
cough. 
Not affected 
5. Samanan  Navel Regulates the digestion 
and controls all the other 
vayus. 
Affected 
6. Nagan Eyes Helps in opening and 
closing of the eyes, 
intelligence. 
Not affected 
7. Koorman Eye Responsible for vision, 
closure of eyelids. 
Not affected 
8. Kirukaran  Saliva Secretion of saliva and 
mucous secretion in nasal 
cavity, helps 
concentration. 
May be 
affected 
9. Devathathan Ocular muscles It is responsible for 
laziness and eyeball 
movements 
May be 
affected 
10. Thananjeyan - It is responsible for 
degradation of body after 
death 
- 
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Pitham: 
 
Sl. 
No. Pitham Functions 
In Thandaga 
Vatham 
1. Analagam Digestion May beaffected  
2. Ranjagam Gives colour to blood May be affected 
3. Sathagam Responsible for wilful activities Affected 
4. Prasagam Gives luster to skin Not affected 
5. Alosagam Gives strength to eyes Not affected 
 
 
Kapham: 
 
Sl. 
No. Kapham Functions 
In Thandaga 
Vatham 
1. Avalambagam Respiratory function Not affected 
2. Klethagam It lubricates the food May be affected 
3. Pothagam Responsible for taste sensation Not affected 
4. Tharpagam It acts as coolent for eyes Not affected 
5. Santhigam It maintains the integrity of joints Affected 
 
 
DIFFERENTIAL DIAGNOSIS: 
 
Thandaga Vatham is different from the following diseases, 
 
1. MRtjk;g thjk;:; ;; ;; ;  
 
‘thjkh Aly;ntSj;J tonty; yhNeuk; 
kaf;fNkh bUkyh a+is Az;lhk; 
Nejkha; neQ;rilj;jg; nghwp fyq;Fk; 
neUg;ghf cly;fhZ neL%r;Rz;lhk; 
NfhJjhd; kaf;fj;jpy; kUe;jp ePl;lhy; 
FspHr;rpaha;f; Nfhgpf;Fq; $r;rYz;lhk; 
ghje;jhd; jpkpUz;lha; Kl;NghyhFk; 
gLj;j MRtjk;gk; gfuyhNk” 
    - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
      (ghly; vz;.284> gf;fk; vz;.108) 
 
 
 
24 
 
The clinical features are: 
 
1. Paleness of the body 
2. Cough 
3. Heaviness of chest 
4. Numbness of both lower limbs 
5. Pain present in vertebral column 
 
2. CUj;jk;g thjk;:; ; ;; ; ;; ; ;  
 
‘Mnkd;w thjkJ cs;s lq;fp 
Mbj;Jiljhd; Fwq;fpuz;L kstha;g; gw;wp 
fhnkdw; iffhypy; tpuY Rw;wpf; 
fdj;JNk rhzpaJ nghjpe;jhH Nghyj; 
Njnkd;w rpue;jdpNy ghu Kz;lha;j;  
Njnkq;F %jpNa jpkpUz;lhFk; 
ehnkd;w elf;nfhzu nthLf;f khfp 
eypa+Ue; jk;gkJ eDFq;fhNd” 
    - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
     (ghly; vz;.260> gf;fk; vz;.98) 
 
 The clinical features are, 
 
1. Heaviness in both thighs. 
2. Feelings of cow dung applied over fingers of both hands and feet. 
3. Whole body perceives numbness. 
4. Difficulty in walking. 
 
3. thj];jk;gk;:; ; ;; ; ;; ; ;  
 
‘cw;gtpf;Fk; thjkJ vOe;J nghq;fp 
caHfhypd; Gwtbiaf; File;J gw;wp 
njw;gtpf;Fk; tPf;fkha;r; nrOk;g Yz;lha;j;  
Njfnkq;Fk; Nehthfpj; jpkpU khfp 
tpw;Gtpf;Fk; tpy;YNghy tpjdkhfp 
kpLf;fhd khe;jidg; Nghy; tpjdkhfp 
gw;gtpf;Fk; gud;widNa epidah%H 
gLfpd;w thj];jk; gKkhk; ghNu” 
    - a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
     (ghly; vz;.254> gf;fk; vz;.96) 
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The clinical features are, 
 
1. Dorsum of the feet gets affected, they look shining with odema, intense 
pain. 
2. Whole body appears to be weak and fatigue. 
3. Body is bend like a bow. 
4. Makes a strong built man to bend and bow while walking. 
 
In Thandaga Vatham, diffuse low back pain, stiffness, radiating pain to lower 
limbs, yellow coloured stools and urine are present. 
 
b). MODERN ASPECTS 
 
Lumbar Spondylosis is a form of lower back pain and is an important clinical, 
social, economic and public health problem affecting the worldwide population. It is a 
disorder with many possible etiologies and many definitions.  
 
DEFINITION: 
 
Lumbar spondylosis, also known as lumbar osteoarthritis can be described as 
all degenerative conditions affecting the discs, vertebral bodies, and associated joints 
of the lumbar vertebrae. Spondylosis of lumbar region is considered as the 
hypertrophic response of adjacent vertebral bone to disc degeneration (although 
osteophytes may infrequently form in the absence of diseased discs)  
 
 
TACKLING THE TERMINOLOGY: 
 
The terms lumbar osteoarthritis, disk degeneration, degenerative disk disease, 
and spondylosis are used in the literature to describe anatomical changes to the 
vertebral bodies and intervertebral disc spaces that may be associated with clinical 
pain syndromes. Within the literature, lumbar spondylosis encompasses numerous 
associated pathologies including spinal stenosis, degenerative spondylolisthesis, 
osteoarthritis, spinal herniation. 
 
 
 
 
26 
 
 
EPIDEMIOLOGY: 
 
Age: 
 
The incidence of lumbar spondylosis is 27-37% of the asymptomatic lower 
back pain population.  Worldwide, more than 80% of individuals older than 40 years 
have lumbar spondylosis, increasing from 3% of individuals aged 20-29 years. 
Approximately 84% of men and 74% of women have vertebral osteophytes, most 
frequently at T9-10 and L3 levels. Approximately 30% of men and 28% of women 
aged 55-64 years have lumbar osteophytes. Approximately 20% of men and 22% of 
women aged 45-64 years have lumbar osteophytes. 
Sex: 
 
Sex ratio reports have been variable but are essentially equal. Gender seems to 
be distinctly in the form of lumbar spondylosis, and disc space narrowing with or 
without osteophytes in women may be a risk factor for low back pain. 
 
CAUSES AND RISK FACTORS: 
 
There are primary and secondary causes 
 
a) Primary causes: 
 
 The role of heredity: 
 
• Genetic factors likely influence the formation of osteophytes and disc 
degeneration. 50% of the variability found in osteoarthritis can be 
attributed to heriditary factors. Similarly, twin studies evaluating the 
progression of degenerative changes in lumbar MRI imaging suggest 
that approximately half (47-66%) of the variance could be explained 
by genetic and environmental factors, attributing only 2-10% of 
variance to physical loading and resistance training. Another twin 
study revealed a high degree of similarity in signal intensity, disk 
height narrowing, disk bulging, and end-plate changes. A search for 
these underlying genetic factors has identified polymorphisms in genes 
regulating inflammatory pathways and a Vitamin D Receptor allele to 
correspond to radiographic progression of lumbar disc degeneration. 
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• Spinal osteophytosis in post menopausal Japanese women correlated 
with the CC genotype of the transforming growth factor β1 gene. 
• Congenital narrowing of the spinal canal (myelopathty is often seen 
when canal’s sagital diameter is 12mm or less). 
• Segmental defects-Hemi vertebra, Fused Vertebra. 
 
 Metabolic Factors: 
 
• Adiposity is seen as a major risk factor. The spine is designed to carry 
the body's weight and distribute the loads encountered during rest and 
activity. When excess weight is carried, the spine is forced to 
assimilate the burden, which may lead to structural compromise and 
damage. One region of the spine that is most vulnerable to the effects 
of obesity is the low back-the lumbar spine. 
• Smoking - Bone is a living tissue dependent on the functions and 
support provided by the other body systems. When these systems are 
not able to perform normally, bone is unable to rebuild itself. The 
formation of bone is particularly influenced by physical exercise and 
hormonal activity, both of which are adversely affected by cigarette 
smoking.Many smokers have less physical endurance than non-
smokers, mainly due to decreased lung function. Cigarette smoking 
reduces the amount of oxygen in the blood and increases the level of 
harmful substances, such as carbon mono oxide. This combined with 
the effects of smoking on the heart and blood vessels, can limit the 
benefits from physical activity.In men and women, cigarette smoking 
is known to influence hormone function. Smoking increases estrogen 
loss in women who are perimenopausal orpostmenopausal. This can 
result in a loss of bone density and spinal diseases. 
• Alcoholism-Lack of Muscular Support: because alcohol is a natural 
muscle relaxant, consumption can decrease support in the back, 
buttocks, pelvic, and abdomen regions of your body, making the body 
and spine work harder to stay upright. 
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Poor Blood Flow: Blood circulation is one of the affected process of 
drinking,and a lack of proper circulation can lead to muscle, and organ 
damage, as well causing nerves in the spinal column to become 
irritated due to lack of oxygen andblood flow. 
• High triglycerides level- High blood cholesterol and triglycerides 
serum levels are risk factors for atherosclerosis, which could be 
responsible for a decreased in the blood supply to the already poor 
vascularized IVD (Inter Veretebral Disc]. At tissue level, structures 
with precarious nutrient supply, such as the IVD, may suffer and 
gradually degenerate as a consequence of failure of nutrient supply to 
IVD cells  
• High blood pressure 
• High blood glucose level-Diabetes is a multi organ disease that affects 
many types of connective tissues, including bone and cartilage.It 
causes the ossification of the posterior longitudinal ligaments and 
bone, which leads to spinal stenosis and nerve pressure. 
 
 The influence of age: 
 
• The aging process to be the strongest risk factor for bony degeneration, 
particularly within the spine.It is found increasing age to be 
significantly associated with osteophyte formation but not predictive of 
the degree of disc space narrowing. 
 
 The impact of activity and occupation: 
 
• Disc generation has long been associated with certain activities. 
Retrospective of Body Mass Index (BMI), incident back trauma, daily 
spineloading (twisting, lifting, bending, and sustained non-neutral 
postures), and whole bodyvibration (such as vehicular driving) to be 
factors which increase both the likelihood and severity of spondylosis. 
 
 Vicious attitude 
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b) Secondary causes: 
 
 Osteo arthritis 
 Rheumatoid arthritis 
 Metastatic carcinoma 
 Lymphoma of Spine 
 TB  Spine 
 Road  accidents 
 Accidental Injury 
 Old Lumbar Fracture 
 Past spine surgery 
 Acquired  narrowing of  lumbar spinal canal dueto 
 
• Osteophytes: Osteophyte formation may represent a remodeling 
process, functionally adapting to the instability or the changes in the 
demands of the spine. Likewise, it emphasizes the dynamic and 
reparative qualities of the intervertebral disc, responding to variations in 
mechanical loading and influencing vertebral kinematics. Osteophytes 
may form in the absence of other degenerative processes, and 
cartilaginous damage may exist without corresponding osteophytes. 
Although there remains a strong association between the presence of 
osteophytes and other degenerative spine changes, isolated instances of 
one without the other occur, in the absence of overt symptoms. 
• Sacralisation of L5 vertebrae 
• Ossified Posterior Longitudinal Ligament(OPLL) 
•  Facet joint hypertrophy(results foraminal stenosis&compression of 
root of radiculo arthropathy) 
• Hypertrophied ligamentum flavum(Compress the cord during 
extension) 
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PATHOPHYSIOLOGY: 
 
The high incidence of simultaneous degenerative changes to the intervertebral 
disc, vertebral body, and associated joints suggests a progressive and dynamic 
mechanism, with interdependent changes occurring secondary to disc space 
narrowing. 
 
Intervertebral Joints: 
 
Adjoining vertebrae are connected to each other at three joints. There is a 
median joint between the vertebral bodies and two joints right and left between the 
articular processes. 
 
The joints between the articular processes are plane synovial joints. 
 
The joint between the vertebral bodies is a symphysis. The surfaces of the 
vertebral bodies are lined by thin layers of hyaline cartilage. Between these layers of 
hyaline cartilage there is a thick plate of fibrocartilage which is called the 
intervertebral disc. 
 
Intervertebral Discs: 
 
These are fibrocartilaginous discs which intervene between the bodies of 
adjacent vertebrae and bind them together. Their shape corresponds to that of the 
vertebral bodies between which they are placed. The thickness of the disc varies in 
different regions of the vertebral column, and in different parts of the same disc. In 
the cervical and lumbar regions the discs are thicker in front than behind, while in the 
thoracic region they are of uniform thickness. The discs are thinnest in the upper 
thoracic region and thickest in the lumbar region. 
 
The discs contribute about one-fifth of the length of the vertebral column. The 
contribution is greater in the cervical and lumbar regions than in the thoracic region.  
 
Each disc is made up of the following two parts: 
 
1. Nucleus Pulposus is the central part of the disc. It is soft and gelatinous at 
birth. It is kept under tension and acts as a hydraulic shock absorber. With 
advancing age the elasticity of the disc is much reduced. 
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2. Annulus Fibrosus forms the peripheral part of the disc. It is made up of a 
narrower outer zone of collagenous fibres and a wider inner zone of 
fibrocartilage. The fibres from laminae that are arranged in the form of 
incomplete rings. The rings are connected by strong fibrous bands. The outer 
collagenous fibres blend with the anterior and posterior longitudinal 
ligaments. 
 
Intervesrtebral discs are believed to undergo a “degenerative cascade” of three 
overlapping phases that may occur over the course of decades. 
Phase-I (Dysfunction Phase): 15to 45 yearsdescribes the initial effects of 
repetitive micro trauma with the development of circumferential painful tears of the 
outer, innervated annulus, and associated end-plate separation that may compromise 
disk nutritional supply and waste removal. Such tears may coalesce to become radial 
tears, more prone to protrusion, and impact the disc’s capacity to maintain water, 
resulting in desiccation and reduced disk height. Fissures may become ingrown by 
vascular tissue and nerve endings, increasing innervation and the disc’s capacity for 
pain signal transmission. 
 
Phase-II (Instability Phase):  35 to70 yearsis characterized by the loss of 
mechanical integrity, with progressive disc changes of resorption, internal disruption, 
and additional annular tears, combined with further facet degeneration that may 
induce subluxation and instability.  
 
Phase-III (Stabilization Phase): 60 years and above is continued disc space 
narrowing and fibrosis occurs along with the formation of osteophytes and transdiscal 
bridging. 
 
There is a spectrum of pathological changes in facial joints and the disc and 
the interaction of these changes. Adjacent pedicles approximate with a narrowing of 
the superior-inferior dimension of the intervertebral canal. Laxity due to 
modestredundancy of the longitudinal ligaments enables bulging of the ligamentum 
flavum and potential for spine instability. Increased spine movement permits 
subluxation of the Superior Articular Process (SAP), causing a narrowed 
anteroposterior dimension of the intervertebral and upper nerve root canals. Laxity 
may also translate into altered weight mechanisms and pressure relationships on 
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vertebral bone and joint spaces believed to influence osteophyte formation and facet 
hypertrophy to both inferior and superior articular processes with risks for projection 
into the intervertebral canal and central canal, respectively. Oblique orientations of 
the articular processes may further cause retrospondylolisthesis, with resulting 
anterior encroachment of the spinal canal, nerve root canal, and intervertebral canal. 
 
Biochemical research exploring osteophyte formation supports the above 
process. Osteophyte lipping is believed to form at periosteum through the 
proliferation of peripheral articular cartilage which subsequently undergoes 
endochondral calcification and ossification. Changing weight mechanics and pressure 
forces as well as alterations in oxygen tension and dynamic fluid pressure appear to be 
influential factors in osteophyte formation. Mesenchymal stem cells of the synovium 
or periostium are likely precursors, with synovial macrophages and a milieu of growth 
factors and extracellular matrix molecules acting as probable mediators in this 
process. 
 
SIGNS AND SYMPTOMS: 
 
When a patient suffers from lumbar spondylosis, it is possible that osteophytes 
are formed. These osteophytes are bony overgrowths that occur due to the stripping of 
the periost from the vertebral body.  
 
 Pain- can be produced when a neural foraminal stenosis is formed, which 
comes from the formation of osteophytes.  
 Joint stiffness, which can limit motion.  
 Neurologic claudication, which includes:  
• Lower back pain,  
• Leg pain,  
• Numbness when standing and walking.  
 Radiating  pain towards  the  lower extremities 
 Diffuse  tenderness  in  lumbar bone 
 Exacerbation  of  pain  on  movements 
 Pain increased  on forward  bending, sneezing, coughing 
 Paraesthesia  and  sensory loss on  affected  area 
 Burning  and  tingling sensation  in  lower limb 
 Pain  and  stiffness   in  low  back in  the morning  hours 
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Less Common Symptoms: 
 
 Loss of balance 
 Neurogenic  bladder. 
 
EXAMINATION: 
 
When a physician performs an examination for lumbar spondylosis, it is 
advised to follow the principles of the general spine examination and apply them to 
this specific pathology. General examination of the spine: 
 
• The examination should begin with careful observation during the whole 
consultation. 
• It is essential to observe the patient's gait and posture.  
1. Inspection: 
 
• Inspection of the entire spine.  
• Look for any obvious swellings or surgical scars. 
• Assess for deformity: scoliosis, kyphosis, loss of lumbar lordosis 
orhyperlordosis of the lumbar spine. Look for shoulder asymmetry andpelvic 
tilt. 
2. Palpation: 
 
• Palpate for tenderness over bone and soft tissues. 
• Perform an abdominal examination to identify any masses and consider a 
rectal examination to exclude other pathologies in this region 
 
Inference: 
 
• No tenderness to palpation is noted, but some discomfort can be elicited with 
deep percussion over the midline of the lumbar area. 
• Physical findings that may also be present include antalgic or normal gait, 
tight lumbar musculature and hamstrings, hyperlordosis, and buttock or thigh 
pain. 
3. Movement: 
 
• Examination of the spine must also include examination of the shoulders and 
examination of the hipsto exclude these joints as a cause of the symptoms. 
 
34 
 
i) To test flexion: 
 
Instruct the patient to bend forwards as much as possible at the waist.    
Normal flexion is 80o or finger tips 3-4 inches from the floor.  
 
ii) Lateral Flexion: 
 
Instruct the patient to bend to the left and to the right as far as possible.Normal 
range is 35oon each side. 
 
iii) Extension: 
 
Instructs the patient to bend at waist as far backward as possible. Normal 
range is 20o-30o.  
 
iv) Rotation:                                                                                                                            
 
Instructs the patient to rotate from the waist to the left and to the right as far as 
possible. Normal range is 45oC possible.Range of motion is full. 
 
4.Neurovascular examination: 
 
• A thorough examination of sensation, tone, power and reflexes should be 
performed. 
• Always consider the possibility of acute spinal cord compression, which is a 
neurosurgical emergency. 
• All peripheral pulses should also be checked, as vascular claudication in the 
upper and lower limbs can mimic symptoms of radiculopathy or canal stenosis  
 
5. Tests for Examination: 
 
• Straight Leg Raising test (SLR) 
• Braggard’s test 
• Femoral nerve stretch test 
• Schober’s test 
• Forward bending to touch the toes 
• Flip test 
• Lassegues test 
• Bowstring sign 
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OUTCOME MEASURES:  
 
Numeric Pain Rating Scale (NPRS): The patient is asked to score 3 pain 
rating, (worse/current/ best) over the last 24hour. The score for this scale is the 
average of these 3 values. This scale is a variant of the VAS but also assess pain 
intensity. 
 
Roland Morris Disability Questionnaire (RMDQ): This questionnaire 
contains sentences that people have used to describe themselves when they have back 
pain on that specific day. As people read the list they might recognize themselves and 
then they must tick that box. A score is appointed according to the amount of boxes 
the patient fills in. This questionnaire makes it possible to follow changes in time. 
Oswestry Disability Index (ODI): This index is made to evaluate how back 
pain invalidates people in their daily activities (sleeping, self-care, sex life, social life 
and travelling). Each question contains 6 categories (0: no limitation 6: most 
limitation). The score is calculated by the sum of the 10 questions, multiplied by 2. 
This value represents the percentage of invalidation.  
 
PainSelf-Efficacy Questionnaire (PSEQ): This questionnaire rates how 
confident patients feel performing activities despite the pain. This is indicated on a 
scale from 0 (no confidence) to 6 (completely confident). All  the scores are then 
added up to a score from 0 to 60. Where the closer to 60 means that the patients have 
a stronger self-efficacy belief. There are also short versions of this questionnaire 
available who shows also a great responsiveness.  
 
Patient-Specific Functional Scale: Questionnaire where patients are asked to 
identify up to three activities that they had difficulty with or are unable to perform as 
a result of their back pain. Each item is given a score of 0-10 (unable- able). The total 
score is assessed by the sum of the activity scores/number of activities (Minimum 
detectable change (90%CI) for average score = 2 points, Minimum detectable change 
(90%CI) for single activity score = 3 points) of all those questionnaires the NRPS is 
recommended for assessing pain because of this ease of administration and 
responsiveness. The ODI and RMDQ are recommended for assessing functioning.  
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DIAGNOSTIC PROCEDURES: 
 
For the clinical diagnosis of lumbar spondylosis, a thorough investigation is 
necessary to ensure that other pathologies are excluded.  
 MRI: Shows the fine details of the spine and is used to visualize the intervertebral 
discs, including the degree of disc herniation, if present. An MRI is also used to 
visualize the vertebrae, the facet joints, the nerves, and the ligaments in the spine 
and can reliably diagnose a pinched nerve. 
 
 X-Rays: show bone spurs on vertebral bodies in the spine, thickening of facet 
joints (the joints that connect the vertebrae to each other), and narrowing of the 
intervertebral disc spaces. 
 
 CT scan: able to visualize the spine in greater detail and can diagnose narrowing 
of the spinal canal (spinal stenosis) when present. 
 
 SPECT: Single-photon emission computed tomography. 
 
 Bone scintigraphy is used to further evaluate patients with suspected spondylosis. 
Controversy surrounds the designation of one of these tests as most useful in the 
evaluation of spondylosis.  
 
 Myelogram: 
 
Helping in detecting: 
 
 Intra spinal lesion 
 Spinal stenosis 
 Any compression of the spinal cord 
 
 Disco graphy 
 
 Nerve conduction studies 
 
 EMG 
 
These procedures were validated in several studies, which concluded that MRI 
was effective (92% sensitivity) in identifying pars lesions. CT scan was also used as a 
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diagnostic procedure, but the result weren’t equally positive. That’s the reason why 
MRI is advised as the best method of diagnosis. 
 
DIFFERENTIAL DIAGNOSIS: 
 
When a patient is suffering from low back pain, there are a lot of possible 
pathologies that could be the cause of this pain. Along with lumbar spondylosis, there 
are other causes as well: 
 
Rheumatoid Arthritis: 
 
Rheumatoid Arthritis (RA) is a long-term autoimmune disorder that primarily 
affects joints. It typically results in warm, swollen, and painful joints. Pain and 
stiffness often worsen following rest. Most commonly, the wrist and hands are 
involved, with the same joints typically involved on both sides of the body. The 
disease may also affect other parts of the body. This may result in a low red blood cell 
count, inflammation around the lungs, and inflammation around the heart. Fever and 
low energy may also be present.Often, symptoms come on gradually over weeks to 
month. 
 
Bekhterev’s Disease (Ankylosing Spondylitis): 
 
Ankylosing Spondylitis (AS) is a type of arthritis in which there is long term 
inflammation of the joints of the spine Typically the joints where the spine joins the 
pelvis are also affected. Occasionally other joints such as the shoulders or hips are 
involved. Eye and bowel problems may also occur. Back pain is a characteristic 
symptom of AS, and it often comes and goes.Stiffness of the affected joints generally 
worsens over time. 
 
Multiple myelomas  
Also known as plasma cell myeloma, is a cancer of plasma cells, a type of 
white blood cell normally responsible for producing antibodies. Initially, often no 
symptoms are noticed. When advanced, bone pain of the affected region, bleeding, 
frequent infections, and anemia may occur 
 
Multiple sclerosis is a long-lasting demyelinating disease in which the insulating 
covers of nerve cells in the brain and spinal cord are damaged, even the optic nerves 
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in eyes. It can cause problems with vision, balance, muscle control, and other basic 
body functions. 
 
Extra dural tumor 
Lumbar Degenerative Disk Disease 
Lumbar Facet Arthropathy  
Osteoporosis 
TB Spine 
SLE 
 
COMPLICATIONS: 
 
 Nerve compression from posterior osteophytes is a possible complication 
only if a neuroforamen is reduced to less than 30% of normal.  
 If lumbar spondylosis projects into the spinal canal, spinal stenosis is a 
possible complication 
 If osteophytes disappear, look for aortic aneurysm. Aortic aneurysms can 
cause pressure erosions of the adjacent vertebrae. If osteophytes are present, 
the first sign is often erosion of those osteophytes, so they are no longer 
visible. 
 An isolated report of a bony L4 mass pressing on the duodenum has been 
described. 
 Cauda equina syndrome 
 Neurogenic claudication 
 Paraplegia 
 Conus Medullaris Syndrome 
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CHAPTER-IV 
 
MATERIALS AND METHODS 
 
 A prospective open labeled randomized clinical study of Thandaga Vatham is 
carried out in Post Graduate Department of Pothu Maruthuvam, Government Siddha 
Medical College and Hospital, Palayamkottai. 
 
Selection of the Cases: 
 
 Totally 40 cases were selected.Out of 40, 20 cases were selected as Inpatients 
and 20 cases treated as Out patients.  These cases were selected from the Outpatient 
Department of Pothu Maruthuvam according to the inclusion and exclusion criteria. 
 
Aetiological factors: 
 
 The seasonal variations and precipitating factors like emotional stress and 
strain, trauma, occupation and food habits were enquired and recorded.  The socio 
economic status, family history and other significant diseases treated already, were 
thoroughly registered.  
 
Inclusion criteria: 
 
 Age: 30-60years. 
 Sex: Both sex. 
 Pain in low back area, radiating pain to buttocks and lower limbs, 
tingling sensation.  
 Stiffness present in the low back area. 
 Exacerbation of pain on movements. 
 Pain increased on forward bending. 
 Patient willing to undergo radiological and provide blood and urine 
samples for laboratory investigation. 
 Patient willing to sign the informed consent stating that he / she will 
consciously stick to the treatment during 30 days but can opt out of the 
trial of his / her conscious discretion.  
 Back pain functional scale score should be below 30.  
  
40 
 
Exclusion criteria: 
 
 Age below 30 years and above 60 years 
 Diabetes mellitus 
 Auto immune disease like SLE, RA 
 Chronic kidney disease 
 Fracture of spine 
 Tuberculosis of spine 
 Congential spino vertebral deformities 
 Cardiac disease 
 Endocrine disorders 
 Malignancy 
 Systemic hypertension 
 Pregnancy and lactation 
 Osteomyelitis 
 Liver disorder 
 Chronic alcoholic and smokers 
 
Diagnosis: 
 
 The diagnosis is made by following Siddha diagnosis methods: 
 
 Poriyal aridhal 
 Pulanal aridhal 
 Vinadhal 
 Envagai thervugal 
 Udal thathukkal 
 Kaalam 
 Nilam 
 
Haematological Investigations: 
 
• HB% 
• Total WBC Count 
• Differential Count 
• Erythrocyte Sedimentation Rate 
• Blood Sugar R/PP/F 
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• Blood Urea 
• Serum Cholesterol 
• Serum Creatinine 
• Serum Uric Acid 
 
Urine analysis: 
 
a) Albumin 
b) Sugar 
c) Deposits 
 
Specific Investigations: 
 
a) RA factor 
b) ASO titre 
c) CRP 
 
Radiological Investigations: 
 
• X-Ray of Lumbar Spine (AP and lateral view) 
 
Assessment of result: 
 
 The results were assessed on the basis of symptomatic relief, improvement in 
back pain functional assessment scale. 
 
 The difference in the score before and after treatment represents the 
improvement in the treatment. 
 
 Further the biochemical, pharmacological and acute toxicity studies were done 
in Government Siddha Medical College, Palayamkottai and K.M. College of 
Pharmacy, Madurai, Tamilnadu. 
 
Statistical Analysis: 
 
 Data were analysed using student’s paired t, test using the prism graph pad 
software.  The result were expressed as Mean ± Standard Deviation and P Values 
<0.001 was observed as statistically significant.  
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Treatment: 
 
 The clinical trial drug “VAEPPAM PATTAI KUDINEER” 50ml twice a 
day after food for 30 days till the end of the course. 
 
 All the patients admitted for the study were given uniformly regular hospital 
diet. 
  
After discharge all the patients were advised to attend the Out patient 
Department of Pothu Maruthuvam, Government Siddha Medical College and 
Hospital, Palayamkottai for further follow up. 
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CHAPTER-V 
 
RESULTS AND OBSERVATIONS 
 
 The results were observed regarding the following criteria by clinical trial 
study on 40 patients. 20 Out patients and 20 In patients of both sex.  The criteria were. 
1. Age Distribution 
2. Sex Distribution 
3. Kaalam 
4. Paruvakaalam 
5. Thinai 
6. Constitution of body 
7. Gunam 
8. Religion 
9. Socio-Economical Status 
10. Food Habits 
11. Family History 
12. Occupation 
13. Aetiological Factors 
14. Mode of Onset 
15. Duration of Illness 
16. Clinical Manifestation 
17. Kanmenthiriyam 
18. Gnanendrium 
19. Kosam 
20. Condition of Mukkutram 
a). Vatham  
b). Pitham 
c). Kapham 
21. Involvement of Udal Thathukkal 
22. Conditions of Envagai Thervugal 
23. Neer Kuri 
24. Nei Kuri 
25. Radiological Findings 
26. Back Pain Functional Score Scale 
27. Gradation of results 
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1. AGE DISTRIBUTION 
 
Table-1 Illustrates the distribution of age and its percentage. 
 
 
TABLE-1 
 
AGE DISTRIBUTION 
 
Sl. 
No. 
Age group 
(In years) 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 21-30 - - - - 
2. 31-40 9 45% 5 25% 
3. 41-50 9 45% 10 50% 
4. 51-60 2 10% 5 25% 
 Total 20 100% 20 100% 
 
FIGURE-1 
AGE DISTRIBUTION 
 
 
 
 From the above table, it is observed that the highest incidence of Thandaga 
Vatham in 20 Out patient is among the age group of 51-60 with 40% and among 20 In 
patients also in the age group of 51-60 with 65%. 
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2. SEX DISTRIBUTION 
 
 Table-2 Illustrates the distribution of sex and its percentage. 
 
TABLE-2 
 
SEX DISTRIBUTION 
 
Sl. 
No. Sex 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Male 12 60% 13 65% 
2. Female 8 40% 7 35% 
 Total 20 100% 20 100% 
 
 
FIGURE-2 
SEX DISTRIBUTION 
 
 
 
From the above table, it is observed that among 20 Out patients 60% were 
males and 40% were females and among 20 In patients 35% were males and 65% 
were females. 
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3. KAALAM 
 
 Table-3 Illustrates the distribution of kaalam and its percentage. 
 
TABLE-3 
 
DISTRIBUTION OF KAALAM 
 
Sl. 
No. Kaalam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatham 1 5% - - 
2. Pitham 19 95% 20 100% 
3. Kapham - - - - 
 Total 20 100% 20 100% 
 
FIGURE-3 
DISTRIBUTION OF KAALAM 
 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients is in Pitha Kaalam with 95% and among 20 In 
patients, is also Pitha Kaalam with 100%.  
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4. PARUVA KAALAM 
 
 Table-4 Illustrates the distribution of paruva kaalam and its percentage. 
 
TABLE-4 
 
DISTRIBUTION OF PARUVA KAALAM 
 
Sl. 
No. Paruva Kaalam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Elavenil Kaalam - - 6 30% 
2. Muthuvenil Kaalam - - - - 
3. Kaar Kaalam - - - - 
4. Koothir Kaalam 5 25% 2 10% 
5. Munpani Kaalam 9 45% - - 
6. Pinpani Kaalam 6 30% 12 60% 
 Total 20 100% 20 100% 
 
FIGURE-4 
DISTRIBUTION OF PARUVA KAALAM 
 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 15 Out patients is in Munpani Kaalam and among 17 In patients is in 
Pinpani Kaalam. 
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5. THINAI 
 
 Table-5 Illustrates the distribution of thinai and its percentage. 
 
TABLE-5 
 
DISTRIBUTION OF THINAI 
 
Sl. 
No. Thinai 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kurinji - - - - 
2. Mullai - - - - 
3. Marutham 20 100% 14 70% 
4. Neithal - - 6 30% 
5. Paalai - - - - 
 Total 20 100% 20 100% 
 
FIGURE-5 
DISTRIBUTION OF THINAI 
 
 
From the above table, it is observed that highest incidence of Thandaga 
Vatham among 20 Out patients were in the Marutham Thinai with 100% and among 
20 In Patients also in Marutham Thinai with 70%.  
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6. CONSTITUTION OF BODY 
 
 Table-6 Illustrates the distribution of constitution of the body and its 
percentage. 
TABLE-6 
 
DISTRIBUTION OF CONSTITUTION OF BODY 
Sl. 
No. Constitution of body 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatham 16 80% 15 75% 
2. Vatha Pitham - - - - 
3. Vatha Kapham - - - - 
4. Pitham 4 20% 5 25% 
5. Pitha Vatham - - - - 
6. Pitha Kapham - - - - 
7. Kapham - - - - 
8. Kapha Vatham - - - - 
9. Kapha Pitham - - - - 
 Total 20 100% 20 100% 
 
FIGURE-6 
DISTRIBUTION OF CONSTITUTION OF BODY 
 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients is Vatha Thegi with 60% and among 20 In patients is 
also Vatha Thegi with 50%. 
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7. GUNAM 
 
 Table-7 Illustrates the distribution of gunam and its percentage. 
 
TABLE-7 
 
DISTRIBUTION OF GUNAM 
 
Sl. 
No. Gunam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Sathuvam - - - - 
2. Rajo 20 100% 20 100% 
3. Thamasa / Thamo - - - - 
 Total 20 100% 20 100% 
 
FIGURE-7 
DISTRIBUTION OF GUNAM 
 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients and 20 In patients with cent percent belongs to Rajo 
Gunam. 
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8. RELIGION 
 
 Table-8 Illustrates the distribution of religion and its percentage. 
 
TABLE-8 
 
DISTRIBUTION OF RELIGION 
 
Sl. 
No. Religion 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Hindu 16 80% 19 95% 
2. Christian - - 1 5% 
3. Muslim 4 20% - - 
 Total 20 100% 20 100% 
 
FIGURE-8 
DISTRIBUTION OF RELIGION 
 
 
 
From the above table, it is observed that among 20 Out patients 80% were 
Hindus, 15% were Christians and 20% were Muslims and among 20 In patients 95% 
were Hindus, 5% were Christians.  
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9. SOCIO-ECONOMICAL STATUS 
 
 Table-9 Illustrates the distribution of socio-economical status and its 
percentage. 
 
TABLE-9 
 
DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 
Sl. 
No. 
Socio-Economical 
Status 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. High  income class - - - - 
2. Middle income class 4 20% 6 30% 
3. Low income class 16 80% 14 70% 
 Total 20 100% 20 100% 
 
FIGURE-9 
DISTRIBUTION OF SOCIO-ECONOMICAL STATUS 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients is in Low income class with 80% and among 20 In 
patients is in Low Income class with 70%.  
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10. FOOD HABITS 
 
 Table-10 Illustrates the 
 
 
Sl. 
No. Food Habits
1. Vegetarian
2. Non-Vegetarian
 
 
 
From the above table, it is observed that 
Vatham among 20 Out patients i
patients is also in Non-
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TABLE-10 
 
DISTRIBUTION OF FOOD HABITS 
 
Out Patients (OP) 
No. of 
cases 
Percentage 
(%) 
 2 10% 
 18 90% 
Total 20 100% 
FIGURE-10 
DISTRIBUTION OF FOOD HABITS 
the highest incidence of Thandaga 
sin Non-Vegetarians with 90% and among 20 In 
Vegetarians with 70%. 
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In Patients (IP) 
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11. FAMILY HISTORY
 
 Table-11 Illustrates the family history and its percentage. 
 
 
Sl. 
No. Family History
1. Positive 
2. Negative 
 
 
 
 
From the above table, it is observed that among 20 Out patients and 20 In 
patients, 15% have positive family history and 85% don’t have 
history. 
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TABLE-11 
 
FAMILY HISTORY 
 
Out Patients (OP) 
No. of 
cases 
Percentage 
(%) 
3 15% 
17 85% 
Total 20 100% 
FIGURE-11 
FAMILY HISTORY 
 
OP %
IP %
 
In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
3 15% 
17 85% 
20 100% 
positive family 
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12. OCCUPATION 
 
 Table-12 Illustrates the occupation and its percentage.   
 
TABLE-12 
 
OCCUPATION 
 
Sl. 
No. Occupation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Agricultural Labours 3 15% 4 20% 
2. Coolie  3 15% 2 10% 
3. House wife 4 20% 5 25% 
4. Tailor 3 15% 2 10% 
5. Load man 1 5% 1 5% 
6. Driver 1 5% 2 10% 
7. Business 3 15% 4 20% 
8. Watchman 2 10% - - 
 Total 20 100% 20 100% 
 
FIGURE-12 
DISTRIBUTION OF OCCUPATION 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients were house wives with 20% and among 20 In patients 
is also house wives with 25%. 
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13. AETIOLOGICAL FACTORS 
 
 Table-13 ISllustrates the aetiological factors and its percentage.   
 
TABLE-13 
 
AETIOLOGICAL FACTORS 
 
Sl. 
No. Aetiological Factors 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Age (30-60 years) 14 70% 16 80% 
2. Occupation 4 20% 3 15% 
3. Trauma  - - - - 
4. Obesity 2 10% 1 5% 
 Total 20 100% 20 100% 
 
FIGURE-13 
AETIOLOGICAL FACTORS 
 
 
From the above table, it is observed that the highest incidence of Thandaga 
Vatham among 20 Out patients is due to age related aetiological factors with 70% and 
among 20 In patients is also due to age related aetiological factors with 80%. 
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14. MODE OF ONSET 
 
 Table-14 Illustrates the mode of onset and its percentage.   
 
TABLE-14 
 
MODE OF ONSET 
 
Sl. 
No. Mode of Onset 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Acute - - - - 
2. Chronic 20 100% 20 100% 
 Total 20 100% 20 100% 
 
FIGURE-14 
MODE OF ONSET 
 
 
 
From the above table, it is observed that among 20 Out patients, 90% were in 
chronic state and among 20 In patients, 100% were in chronic state. 
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15. DURATION OF ILLNESS 
 
 Table-15 Illustrates the duration of illness and its percentage.   
 
TABLE-15 
DURATION OF ILLNESS 
Sl. 
No. Duration of illness 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. 15-30 Days - - - - 
2. 1-3 Months - - - - 
3. 3-6 Months 1 5% 2 10% 
4. 6-9 Months 2 10% 2 10% 
5. 9-12 Months 3 15% 4 20% 
6. Above 12 Months 14 70% 12 60% 
 Total 20 100% 20 100% 
 
FIGURE-15 
DURATION OF ILLNESS 
 
 
From the above table, among 20 Out patients, duration of illness 15% were 
15-30 days, 25% were 1-3 months, 15% were 3-6 months, 10% were 6-9 months, 
10% were 9-12 months, 25% were above 12 months. Among the 20 In patients, 
duration of illness 20% were 1-3 months, 25% were 3-6 months, 5% were 6-9 
months, 25% were 9-12 months, 25% were above 12 months were observed. 
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16. CLINICAL MANIFESTATION 
 
 Table-16 Illustrates the clinical manifestation and its percentage.   
 
TABLE-16 
 
CLINICAL MANIFESTATION 
 
Sl. 
No. 
Clinical 
Manifestation 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Low back pain  20 100% 20 100% 
2. Radiating pain 17 85% 20 100% 
3. Restricted movements 9 45% 11 55% 
4. Stiffness 7 35% 9 45% 
5. Tenderness 10 50% 5 25% 
6. Exacerbation of pain 
on movements 20 100% 20 100% 
7. Numbness 6 30% 7 35% 
 
 
 From the above table, it is observed that, among 20 Out patients, 100% of 
cases have low back pain and exacerbation of pain on movements.  85% have 
radiating pain, 45% have restricted movements, 35% have stiffness, 35% have 
tenderness and 30% have numbness.  Among20 In patients 100% of cases have low 
back pain, radiating pain and exacerbation of pain on movements. 55% have restricted 
movements, 45% have stiffness, 25% have tenderness and 35% have numbness. 
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FIGURE-16 
CLINICAL MANIFESTATION 
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17. KANMENTHIRIYAM 
 
 Table-17 Illustrates the kanmenthiriyam and its percentage.   
 
TABLE-17 
 
KANMENTHIRIYAM 
 
Sl. 
No. Kanmenthiriyam 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Kai - - - - 
2. Kaal 17 85% 20 100% 
3. Vai - - - - 
4. Eruvai 7 35% 5 25% 
5. Karuvai - - - - 
 
FIGURE-17 
KANMENTHIRIYAM 
 
 
 
 From the above table, it is observed that among 20 Out patients, 85% were 
affected in Kaal and 35% in Eruvai.  Among 20 In patients 100% were affected in 
Kaal and 25% in Eruvai.  
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18. GNANENDRIUM 
 
 Table-18 Illustrates the gnanendrium and its percentage.   
 
TABLE-18 
 
GNANENDRIUM 
 
Sl. 
No. Gnanendrium 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Mei 5 25% 6 30% 
2. Vaai - - - - 
3. Kan 2 10% - - 
4. Mooku - - - - 
5. Sevi - - - - 
 
FIGURE-18 
GNANENDRIUM 
 
 
 
From the above table, it is observed that, among 20 Out patients, 25% were 
affected in Mei; 10% were affected in Kan. Among 20 In patients 30% were affected 
in Mei. 
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19. KOSAM 
 
 Table-19 Illustrates the kosam and its percentage.   
 
TABLE-19 
 
KOSAM 
 
Sl. 
No. KOSAM 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Annamaya Kosam 6 30% 5 25% 
2. Pranamaya Kosam - - - - 
3. Manomaya Kosam - - - - 
4. Vingnanamaya Kosam 20 100% 20 100% 
5. Anandamaya Kosam - - - - 
 
FIGURE-19 
KOSAM 
 
 
 
From the above table, it is observed that among 20 Out patients 100% were 
affected withVingnanamaya Kosam and 30% were affected with Annamaya Kosam.  
Among 20 In patients, 100% were affected withVingnanamaya Kosam and 25% were 
affected with Annamaya Kosam. 
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20 (a).CONDITION OF MUKKUTRAM 
 
 (a). VATHAM: 
 
 Table-20 (a) Illustrates the condition of vatham and its percentage.   
 
TABLE-20 (a) 
 
CONDITION OF VATHAM 
 
Sl. 
No. Condition of Vatham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Piraanan - - - - 
2. Abaanan 7 35% 5 25% 
3. Viyaanan 20 100% 20 100% 
4. Uthaanan - - - - 
5. Samaanan 20 100% 20 100% 
6. Naagan - - - - 
7. Koorman 2 10% - - 
8. Kirukaran 6 30% 5 25% 
9. Devathathan 20 100% 20 100% 
10. Dhananjayan - - - - 
 
 
From the above table, it is observed that among 20 Out patients 100% were 
affected in Viyaanan, Samaanan and Devathathan; 35% were affected in Abaanan; 
10% were affected in Koorman; 30% were affected in Kirukaran;  Among 20 In 
patients 100% were affected in Viyaanan, Samaanan and Devathathan; 25% were 
affected in Abaanan. 
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FIGURE-20 (a) 
 
CONDITION OF VATHAM 
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20 (b).PITHAM 
 
 Table-20 (b) Illustrates the condition of pitham and its percentage.   
 
TABLE-20 (b) 
 
CONDITION OF PITHAM 
 
Sl. 
No. 
Condition of 
Pitham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Analagam 6 30% 5 25% 
2. Ranjagam 5 25% 2 10% 
3. Sathagam 20 100% 20 100% 
4. Prasagam - - - - 
5. Aalosagam - - - - 
 
FIGURE-20 (b) 
CONDITION OF PITHAM 
 
 
From the above table, it is observed that among 20 Out patients, 100% were 
affected in Sathagam; 30% were affected in Analagam; 25% were affected in 
Ranjagam; Among 20 In patients, 100% were affected in Sathagam; 25% were 
affected in Analagam; 10% were affected in Ranjagam. 
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20 (c).KAPHAM 
 
 Table-20 (c) Illustrates the condition of kapham and its percentage.   
 
TABLE-20 (c) 
 
CONDITION OF KAPHAM 
 
Sl. 
No. Condition of Kapham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Avalambagam - - - - 
2. Kilethagam 6 30% 5 25% 
3. Pothagam - - - - 
4. Tharpagam - - - - 
5. Santhigam 20 100% 20 100% 
 
FIGURE-20 (c) 
CONDITION OF KAPHAM 
 
 
From the above table, it is observed that among 20 Out patients, 100% were 
affected in Santhigam; 30% were affected in Kilethagam. Among 20 In patients, 
100% were affected in Santhigam; 25% were affected in Kilethagam. 
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21. INVOLVEMENT OF UDAL THATHUKKAL 
 
 Table-21 Illustrates the involvement of udal thathukkal and its percentage. 
  
 
TABLE-21 
 
INVOLVEMENT OF UDAL THATHUKKAL 
 
Sl. 
No. 
Involvement of Udal 
Thathukkal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Saaram 20 100% 20 100% 
2. Senneer 5 25% 2 10% 
3. Oon  - - - - 
4. Kozhuppu 20 100% 20 100% 
5. Enbu 20 100% 20 100% 
6. Moolai - - - - 
7. Sukkilam / Suronitham - - - - 
 
FIGURE-21 
INVOLVEMENT OF UDAL THATHUKKAL 
 
From the above table, it is observed that among 20 Out patients and 20 In 
patients cent percent were affected in Saaram, Kozhuppu, Enbu.  Among 20 Out 
patients, 25% were affected in Senneer and in 20 In patients, 10% were affected in 
Senneer.  
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22. CONDITIONS OF ENVAGAI THERVUGAL 
 
 Table-22 Illustrates the envagai thervugal and and its percentage.   
 
TABLE-22 
 
CONDITIONS OF ENVAGAI THERVUGAL 
 
Sl. 
No. 
Conditions of Envagai 
Thervugal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Naadi (Thontha Naadi)     
 1). Vatha Pitham 16 80% 12 60% 
 2). Vatha Kapham - - 2 10% 
 3). Pitha Vatham 4 20% 6 30% 
 4). Pitha Kapham - - - - 
 5). Kapha Vatham - - - - 
 6). Kapha Pitham - - - - 
2. Sparisam 5 25% 6 30% 
3. Naa - - - - 
4. Niram - - - - 
5. Mozhi - - - - 
6. Vizhi 7 35% 2 10% 
7. Malam 7 35% 5 25% 
8. Moothiram - - - - 
 
 From the above table it is observed that among 20 Out patients, 55% have 
Vatha Pitha Naadi, 25% have Vatha Kapha Naadi and 20% have Pitha Vatha Naadi; 
25% were affected in Sparisam; 35% were affected in Vizhi and Malam.  Among 20 
In patients, 60%  have Vatha Pitha Naadi, 10% have Vatha Kapha Naadi and 30% 
have Pitha Vatha Naadi; 30% were affected in Sparisam; 10% were affected in vizhi; 
25% were affected in Malam. 
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23. NEERKURI 
 
 Table-23 Illustrates the neer kuri and its percentage.   
 
TABLE-23 
 
NEERKURI 
 
Sl. 
No. Neer Kuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Niram 6 30% 7 35% 
2. Manam - - - - 
3. Edai - - - - 
4. Nurai - - - - 
5. Enjal - - - - 
 
FIGURE-23 
NEERKURI 
 
 
 
From the above table, it is observed that among 20 Out patients, 30% were 
affected in Niram.  Among 20 In patients,35% were affected in Niram.  
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24. NEI KURI 
 
 Table-24 Illustrates the neikuri and its percentage.   
 
TABLE-24 
 
NEIKURI 
 
Sl. 
No. Nei Kuri 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Vatha Neer / Spreading like snake 18 90% 17 85% 
2. Pitha Neer / Spreading like ring 2 10% 3 15% 
3. Kapha Neer / Spreading like pearl - - - - 
4. Thontha Neer  - - - - 
5. Asathiya Nei Kurigal - - - - 
 
FIGURE-24 
NEIKURI 
 
 
From the above table, it is observed that among 20 Out patients, 70% have 
Vatha Neer; 10% Pitha Neer; 10% Kapha Neer and 10% Thontha Neer.  Among 20 In 
patiens, 65% have Vatha Neer; 15% Pitha Neer; 10% Kapha Neer and 10% Thontha 
Neer.  
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25. RADIOLOGICAL FINDINGS 
 
 Table-25 Illustrates radiological findings and its percentage.   
 
TABLE-25 
 
RADIOLOGICAL FINDINGS 
 
Sl. 
No. Radiological Findings 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. 
of 
cases 
Percentage 
(%) 
1. Degenerative changes  20 100% 20 100% 
2. Osteophytic changes 14 70% 40 70% 
3. Reduced in IVD space 20 100% 20 100% 
4. Altered lordosis - 0% - 0% 
 
FIGURE-25 
RADILOGICAL FINDINGS 
 
 
 
From the above table, it is observed that among 20 Out patients and 20 In 
patients, cent percent have degenerative and osteophytic changes. Among 20 Out 
patients, 10% have reduced IVD space. Among 20 In patients, 15% have reduced IVD 
space; 10% have reduced lordosis. 
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26. ASSESSMENT OF OUTCOME 
 
(a) Back Pain Functional Scale Score 
 
 Table-26 (a)  Illustrates backpain functional scale score in percentage. 
 
TABLE-26 (a) 
 
BACK PAIN FUNCTIONAL SCORE SCALE 
 
Sl. 
No. 
Assessment 
of Outcome 
(Pain Score) 
Before Treatment After Treatment 
Out 
Patients 
(OP) 
In Patients 
(IP) 
Out 
Patients 
(OP) 
In 
Patients 
(IP) 
N
o
.
 
o
fc
a
se
s 
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rc
en
ta
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(%
) 
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.
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f c
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(%
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.
 
o
f c
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(%
) 
N
o
.
 
o
f c
a
se
s 
Pe
rc
en
ta
ge
 
(%
) 
1. ≤30 20 100% 20 100% 2 10% 2 10% 
2. 31-40 - - - - 2 10% 4 20% 
3. 41-50 - - - - 3 15% - - 
4. 51-60 - - - - 13 65% 14 70% 
 Minimum Score-0, Maximum Score-60 
 
Pain Score Improvement 
≤30 NO 
31-40 Mild 
41-50 Moderate 
51-60 Good 
Reference: 
 
 Stratford PW Binkley JM et al. Development and initial validation of the Back 
pain Functional Scale. Spine.2000; 2095-2102 (Appendix-A Page:2101) 
 
From the above table, it is observed that before treatment among 20 Out 
patients and 20 In patients  were with pain score ≤30. After treatment, among 20 Out 
patients 65% have good improvement; 15%: moderate imporevement; 10% mild 
improvement; 10% no improvement. Among 20 In patient 70% have good 
improvement; 20% mild improvement; 10% no improvement. 
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Table-26 (b) Illustrates BPFSS through Statistical Analysis 
 
TABLE-26 (b) 
                          BPFSS through Statistical Analysis 
 
Sl.No Sample Mean ±SD T Value P Value Result 
BT AT 
1. Out 
Patient 
21.855±5.40 48.20±10.15 10.24 <0.0001 HS 
2. In 
Patient 
20.10±5.71 47.10±11.72 9.26 <0.0001 HS 
(n=20) List wise 
BT - Before Treatment 
AT-After Treatment 
HS - Highly significant. 
 The BPFSS among out and in patients where found to be statistically highly 
significant at P<0.0001 
 
27. GRADATION OF RESULTS 
 
 Table-27Illustrates Gradation of Results and its percentage.   
 
TABLE-27 
 
GRADATION OF RESULTS 
 
Sl. 
No. Results 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Good response 13 65% 14 70% 
2. Moderate response 5 25% 4 20% 
3. Poor response 2 10% 2 10% 
 Total 20 100% 20 100% 
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From the above table, it is observed that 
good response; 25% moderate response; 10% poor response. Among 20 In patients
70% showed good response; 20% moderate response; 10% poor response.
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TABLE-28 (a) 
 
LABORATORY INVESTIGATION (OUT PATIENTS) 
 
Sl. 
No. 
Out 
Patient 
Haematological Report Urine Analysis 
Before Treatment After  Treatment Before Treatment After Treatment 
TC DC ESR 
H
b
%
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s
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b
%
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s
)
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.
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.
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.
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1
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r
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1
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1. 96644 9100 60 38 3 5 28 7.0 7700 65 30 5 6 14 10.5 NIL NIL 1-2 PUS CELLS NIL NIL NAD 
2. 96657 7300 62 33 5 4 20 11.1 8800 62 34 4 8 13 10.9 NIL NIL NAD NIL NIL NAD 
3. 98982 9200 64 30 6 4 9 9 6900 65 32 3 4 12 11 NIL NIL NAD NIL NIL NAD 
4. 99036 9200 60 38 2 2 4 13 9000 61 33 6 2 8 12.1 NIL NIL NAD NIL NIL NAD 
5. 100250 6600 60 34 6 9 42 10.0 8900 62 35 3 5 11 10.5 NIL NIL 1-2PUS CELLS NIL NIL NAD 
6. 110477 6400 59 36 5 7 60 9.2 8300 71 24 5 7 12 12 NIL NIL NAD NIL NIL NAD 
7. 111724 8600 62 30 8 3 16 12.5 9300 63 34 3 2 4 11.3 NIL NIL NAD NIL NIL NAD 
8. 112059 9300 60 38 2 5 15 8.5 7900 61 33 6 3 6 13 NIL NIL NAD NIL NIL NAD 
9. 113104 7500 63 33 4 9 35 11.0 9400 62 33 5 3 9 11.6 NIL NIL NAD NIL NIL NAD 
10. 1131 7800 58 40 2 7 15 13 9200 67 31 2 4 13 12.7 NIL NIL FEW PUS CELLS NIL NIL NAD 
11. 5636 4800 68 29 3 10 2 11.3 9000 66 31 3 8 16 10.8 NIL NIL NAD NIL NIL NAD 
12. 3998 7200 65 30 5 3 32 10.1 8100 66 29 5 9 12 13 NIL NIL NAD NIL NIL NAD 
13. 2039 7700 60 34 6 4 8 7.6 9200 61 36 3 8 12 11.2 NIL NIL NAD NIL NIL NAD 
14. 2352 9200 60 38 2 4 4 12.2 8300 72 24 4 8 14 12.4 NIL NIL 1-2 PUS CELLS NIL NIL NAD 
15. 12532 8500 58 38 4 3 7 13 9200 61 36 3 8 12 10.8 NIL NIL NAD NIL NIL NAD 
16. 12968 8800 62 36 2 4 14 11.6 8300 72 24 4 8 14 11.7 NIL NIL NAD NIL NIL NAD 
17. 15823 8800 60 33 7 7 9 6.9 8500 65 30 5 3 9 10.3 NIL NIL NAD NIL NIL NAD 
18. 15766 6700 64 34 2 9 15 12.3 8200 62 31 7 3 6 11.9 NIL NIL NAD NIL NIL NAD 
19. 15831 8900 61 36 3 8 15 9.2 8000 60 36 4 3 5 11.8 NIL NIL NAD NIL NIL NAD 
20. 23427 7500 64 36 6 9 17 8 9400 65 29 6 5 10 12.3 NIL NIL NAD NIL NIL NAD 
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TABLE-28 (b) 
 
LABORATORY INVESTIGATION (IN PATIENTS) 
 
Sl. 
No. 
In  
Patient 
No. 
Haematological Report Urine Analysis 
Before Treatment After  Treatment Before Treatment After Treatment 
TC DC ESR 
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1. 2952 7000 67 30 3 4 20 10.5 9100 71 27 2 6 11 12 NIL NIL 1-2 Epi. Cells NIL NIL NAD 
2. 3046 7400 60 36 4 9 28 11.5 8300 67 29 4 4 9 11.1 NIL NIL Few Pus Cells NIL NIL NAD 
3. 342 9100 64 32 4 7 13 11.8 8100 59 35 6 4 8 12.5 NIL NIL NAD NIL NIL NAD 
4. 485 6200 63 32 5 5 25 10.4 9500 72 27 1 3 10 13 NIL NIL 1-2 Pus Cells NIL NIL NAD 
5. 561 9900 80 15 5 8 70 10.5 9400 59 38 3 2 5 11.5 NIL NIL Few Pus Cells NIL NIL NAD 
6. 628 8500 65 30 5 3 10 10.4 8500 66 32 2 6 8 10.5 NIL NIL Few Epi. Cells NIL NIL NAD 
7. 633 8600 62 30 8 7 16 12.5 8900 61 36 3 4 13 10.8 NIL NIL NAD NIL NIL NAD 
8. 631 9900 80 75 5 5 70 10.2 8600 65 30 5 6 11 12.8 NIL NIL Few Epi. Cells NIL NIL NAD 
9. 630 6000 64 33 3 6 10 12.9 7000 64 35 1 5 13 10.6 NIL NIL NAD NIL NIL NAD 
10. 629 7900 63 36 2 7 90 11.8 9300 59 39 2 3 7 11.8 NIL NIL NAD NIL NIL NAD 
11. 624 6000 64 33 3 6 10 10.9 8000 63 33 4 4 8 12.4 NIL NIL NAD NIL NIL NAD 
12. 688 7000 65 37 3 5 45 10.4 9100 70 26 4 6 10 13.5 NIL NIL NAD NIL NIL NAD 
13. 719 8400 62 31 7 8 12 12.5 8800 63 33 4 3 6 12.1 NIL NIL NAD NIL NIL NAD 
14. 777 8600 62 34 4 5 15 11.0 8700 64 33 3 6 14 11.6 NIL NIL NAD NIL NIL NAD 
15. 965 8200 63 33 4 5 43 7.0 8400 63 35 2 6 12 10.5 NIL NIL 1-2 Epi. Cells NIL NIL NAD 
16. 1135 7300 60 35 5 7 24 11.6 9200 65 33 2 3 6 10.9 NIL NIL Few Pus Cells NIL NIL NAD 
17. 1137 7000 63 31 3 9 19 12 9000 61 34 5 4 11 11.6 NIL NIL 1-2 Pus Cells NIL NIL NAD 
18. 1136 7300 60 35 5 7 24 11.6 10000 64 32 4 7 12 12.3 NIL NIL Few Pus Cells NIL NIL NAD 
19. 1182 6700 64 32 4 2 24 12.7 9000 62 32 6 4 8 12.9 NIL NIL Few Pus Cells NIL NIL NAD 
20. 1200 6100 65 31 4 8 40 6.7 8700 60 35 5 3 7 11.5s NIL NIL NAD NIL NIL NAD 
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TABLE-29 (a) 
 
LABORATORY INVESTIGATION (OUT PATIENTS) 
 
 
Sl. 
No. OP No. 
Before Treatment After Treatment 
Blood 
Sugar (R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
Blood 
Sugar (R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
1. 96644 82 29 165 3.00 0.50 98 29 146 3.10 0.70 
2. 96657 114 21 168 3.20 0.7 132 27 137 3.00 0.80 
3. 98982 120 27 169 3.80 0.80 115 27 166 3.81 0.80 
4. 99036 134 21 189 4.52 0.70 134 19 168 4.47 0.70 
5. 100250 92 23 200 5.00 0.5 86 25 122 4.89 0.50 
6. 110477 115 15 189 3.40 0.60 100 18 140 3.39 0.70 
7. 111724 129 28 187 3.24 0.90 117 26 189 3.21 0.70 
8. 112059 89 24 190 3.60 0.50 80 23 192 3.58 0.50 
9. 113104 90 26 198 3.50 0.7 94 21 140 3.49 0.80 
10. 1131 81 32 191 3.00 0.9 121 20 183 2.99 0.60 
11. 5636 110 28 189 4.40 0.7 116 22 168 2.49 0.80 
12. 3998 76 14 160 2.50 0.40 101 16 160 4.35 0.40 
13. 2039 90 20 164 4.30 3.60 86 18 154 2.49 0.70 
14. 2352 134 21 189 4.20 0.70 112 19 178 4.30 0.60 
15. 12532 111 24 199 3.70 0.40 122 20 161 4.20 0.90 
16. 12968 75 25 118 3.00 1.00 99 23 128 3.70 0.80 
17. 15823 94 34 163 3.50 0.80 132 30 165 3.10 0.90 
18. 15766 106 24 109 3.00 0.80 129 25 112 3.47 0.80 
19. 15831 126 24 178 4.00 0.90 99 26 176 3.00 0.70 
20 23427 98 30 189 4.00 1.00 116 27 185 4.10 0.40 
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TABLE-29 (b) 
 
LABORATORY INVESTIGATION (IN PATIENTS) 
 
 
Sl. 
No. IP No. 
Before Treatment After Treatment 
Blood 
Sugar (R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
Blood 
Sugar (R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
1. 2952 98 25 200 2.20 0.6 98 23 177 4.60 0.40 
2. 3046 72 16 188 2.40 0.5 95 14 193 2.70 0.60 
3. 342 93 28 193 4.30 0.70 114 27 124 3.10 0.50 
4. 485 121 22 200 3.90 0.7 102 17 196 2.20 0.50 
5. 561 120 21 162 4.00 0.5 136 24 170 3.80 0.80 
6. 628 126 20 176 3.90 0.6 82 20 155 4.50 0.70 
7. 633 97 35 175 3.60 0.40 127 27 149 3.50 1.00 
8. 631 150 18 200 4.10 0.6 105 31 194 5.00 0.80 
9. 630 76 18 200 4.30 0.6 100 32 180 3.50 0.70 
10. 629 62 18 147 5.20 0.7 111 23 182 4.60 0.50 
11. 624 76 18 187 4.40 0.8 125 24 197 2.60 0.80 
12. 688 90 24 165 3.60 0.5 91 27 176 2.20 0.90 
13. 719 109 14 192 4.50 0.80 117 15 177 4.20 0.70 
14. 777 75 31 156 2.80 0.50 112 34 163 4.10 0.40 
15. 965 100 25 172 3.00 0.9 132 25 174 3.80 0.80 
16. 1135 132 18 130 2.20 0.6 80 21 133 3.20 0.90 
17. 1137 110 15 138 4.00 0.7 120 34 140 3.40 0.60 
18. 1136 132 18 130 4.60 0.6 122 26 186 4.60 0.90 
19. 1182 131 19 169 3.80 0.7 101 22 158 4.70 0.60 
20 1200 84 24 166 5.20 0.7 133 26 196 5.50 0.90 
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TABLE-30 (a) 
 
LABORATORY AND RADIOLOGICAL INVESTIGATIONS  
(OUT PATIENTS) 
 
Sl. 
No. OP No. 
RA 
Factor 
(IU / 
ml) 
ASO 
titre  
(IU / 
ml) 
C-
reative 
protin 
(mg/dl) 
Radiological finding 
1. 96644 6.6 90.3 1.6 Spondylotic changes L4 to L5 
2. 96657 19.1 88.4 2.2 Spondylotic changes L3 to L5 
3. 98982 17 79.7 2.5 Spondylotic changes L3 to  L4 
4. 99036 12.5 90.7 2.8 Spondylotic changes L3 to L5 
5. 100250 12.3 79.8 2.6 Spondylotic changes L3 to L5 
6. 110477 10.9 110.3 4.5 Spondylotic changes L3 to L5 
7. 111724 14.1 90.1 5.7 Spondylotic changes L3 to L5 
8. 112059 19.0 49 5.5 Spondylotic changes L4 to L5 
9. 113104 18.1 64.0 1.8 Spondylotic changes L5 to S1 
10. 1131 17.9 78.4 5.9 Spondylotic changes L3 to L4 
11. 5636 12.6 91.2 5.2 Spondylotic changes L3to L4 
12. 3998 11.7 104.0 3.1 Spondylotic changes L4 to S1 
13. 2039 18.4 80.1 4.0 Spondylotic changes L2 to L4 
14. 2352 18 111.0 3.9 Spondylotic changes L3 to L5 
15. 12532 12.4 90.7 1.6 Spondylotic changes L5 to S1 
16. 12968 17.6 88.0 2.7 Spondylotic changes L4 to L5 
17. 15823 17.3 140.0 4.5 Spondylotic changes L3 to L4 
18. 15766 10 93.0 5.4 Spondylotic changes L3 to L5 
19. 15831 8.1 74.0 3.4 Spondylotic changes L1 to L5 
20 23427 9.3 91.2 2.3 Spondylotic changes L3 to L4 
 
Reference Range: 
Rheumatoid Factor: Upto 20 IU/ml 
Serum for ASO: Upto 200IU/ml 
CRP: Upto 6 mg/l 
 
 
  
82 
 
TABLE-30 (b) 
 
LABORATORY AND RADIOLOGICAL INVESTIGATIONS  
(IN PATIENTS) 
 
Sl. 
No. IP No. 
RA 
Factor 
(IU / 
ml) 
ASO 
titre  
(IU / 
ml) 
C-
reative 
protin 
(mg/dl) 
Radiological finding 
1. 2952 8.8 99.9 5.5 Spondylotic changes L5 to S1 
2. 3046 8.2 65.4 3.5 Spondylotic changes L4 to L5 
3. 342 7.3 89.0 2.0 Spondylotic changes L3 to L5 
4. 485 7.8 30.0 4.0 Spondylotic changes L3 to L4 
5. 561 5.5 89.8 5.0 Spondylotic changes L4 to L5 
6. 628 3.5 61.7 2.2 Spondylotic changes L4 to L5 
7. 633 4.7 95.2 5.3 Spondylotic changes L4 to S1 
8. 631 6.8 88.8 1.4 Spondylotic changes L4 to L5 
9. 630 8.7 75.5 2.1 Spondylotic changes L3 to L5 
10. 629 5.3 60.0 5.5 Spondylotic changes L3 to L4 
11. 624 7.4 10.0 3.8 Spondylotic changes L4 to L5 
12. 688 11.4 60.7 3.6 Spondylotic changes L3 to L5 
13. 719 15.7 19.0 5.8 Spondylotic changes L2 to L5 
14. 777 1.30 80.6 3.7 Spondylotic changes L2 to L5 
15. 965 7.0 70.5 4.5 Spondylotic changes L3 to L4 
16. 1135 9.2 100.1 2.5 Spondylotic changes L3 to L5 
17. 1137 5.6 79.9 6.9 Spondylotic changes L3 to L4 
18. 1136 14.2 85.2 3.2 Spondylotic changes L3 to L5 
19. 1182 6.5 50.8 3.5 Spondylotic changes L3 to L4 
20 1200 4.5 92.4 5.2 Spondylotic changes L3 to L5 
 
Reference range:  
Rheumatoid Factor: Upto 20IU/ml  
Serum for ASO: Upto 200 IU/ml  
CRP: Upto 6 mg/L 
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TABLE-31 (a) 
 
BACK PAIN FUNCTIONAL SCALE SCOREVALUES (OUT PATIENTS) 
 
Sl. 
No. OP No. 
Pain score 
Before 
Treatment 
After 
Treatment 
1. 96644 24 56 
2. 96657 17 47 
3. 98982 15 24 
4. 99036 10 27 
5. 100250 20 43 
6. 110477 26 51 
7. 111724 23 53 
8. 112059 16 39 
9. 113104 13 33 
10. 1131 23 52 
11. 5636 30 52 
12. 3998 27 55 
13. 2039 26 57 
14. 2352 28 51 
15. 12532 22 55 
16. 12968 25 53 
17. 15823 21 59 
18. 15766 19 45 
19. 15831 27 54 
20 23427 25 58 
 
Interpretation: 
  ≤30 : No improvement / High disease activity 
  31-40 : Mild improvement 
  41-50 : Moderate improvement 
  51-60 : Good improvement 
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TABLE-31 (b) 
 
BACK PAIN FUNCTIONAL SCALE SCORE VALUES (IN PATIENTS) 
 
Sl. 
No. IP No. 
Pain score 
Before 
Treatment 
After 
Treatment 
1. 2952 20 50 
2. 3046 15 35 
3. 342 27 58 
4. 485 18 52 
5. 561 16 57 
6. 628 24 50 
7. 633 26 53 
8. 631 17 15 
9. 630 19 28 
10. 629 23 51 
11. 624 28 54 
12. 688 30 59 
13. 719 12 55 
14. 777 21 33 
15. 965 22 56 
16. 1135 12 38 
17. 1137 17 53 
18. 1136 13 54 
19. 1182 28 51 
20 1200 14 40 
 
Interpretation: 
 ≤30 : No improvement / High disease activity 
 31-40 : Mild improvement 
 41-50 : Moderate improvement 
 51-60 : Good improvement 
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TABLE-32 (a) 
 
CASE SUMMARY (OUT PATIENTS) 
 
Sl. 
No. OP No. Name 
Age / 
Sex Occupation 
Duration 
of illness 
Treatment 
starting date 
End of 
treatment Total Days Results 
1. 96644 Kala 57/F House Wife  1 ½ Years 3.11.17 2.12.17 30 Good 
2. 96657 Paasha 39/M Business 4 Years 3.11.17 2.12.17 30 Fair 
3. 98982 Kathiresan 48/M Agricultural labour 10 Months 10.11.17 9.12.17 30 Poor 
4. 99036 Manthiram 35/M Coolie 11 Months 10.11.17 9.12.17 30 Poor 
5. 100250 Isakiammal 58/F House wife 6 Months 14.11.17 13.12.17 30 Fair 
6. 110477 Velammal 37/F House wife 5 Years 14.12.17 12.1.18 30 Fair 
7. 111724 Siva Ganam 58/F House wife 3 Years 18.12.17 16.1.18 30 Poor 
8. 112059 Murukesan 59/M Watchman 2 ½ Years 19.12.17 17.1.18 30 Fair 
9. 113104 Nisha 38/F Tailor 2 Years 22.12.17 20.1.18 30 Fair 
10. 1131 Guru Dhas 60/M Watchman 2 Years 3.1.18 1.2.18 30 Good 
11. 5636 Arumuga Samy 41/M Agricultural labour 2 Years 10.1.18 8.2.18 30 Good 
12. 3998 Thankam 43/F Coolie 1 Year 10.1.18 8.2.18 30 Good 
13. 2039 Thanka Raj 56/M Driver 7 Years 12.1.18 10.2.18 30 Good 
14. 2352 Seyyed Ali 43/M Tailor 3 Years 24.1.18 22.2.18 30 Good 
15. 12532 Abdhul Kaadhar 40/M Agricuitural labour 3 years 6.2.18 7.3.18 30 Good 
16. 12968 Maari Muthu 38/M Business 6 Years 7.2.18 8.3.18 30 Good 
17. 15823 Kumar 39/M Business 4 Months 1.3.18 30.3.18 30 Good 
18. 15766 Sankar 31/M Loadman 3 Years 1.3.18 30.3.18 30 Good 
19. 15831 Jegadeeshwari 40/F Coolie 8 Months 1.3.18 30.3.18 30 Good 
20. 23427 Ayisha 53/F Tailor 4 Years 9.3.18 7.4.18 30 Good 
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TABLE-32 (b) 
 
CASE SUMMARY (IN PATIENTS) 
 
Sl. 
No. IP No. Name 
Age / 
Sex Occupation 
Duration 
of illness 
Treatment 
starting 
date 
End of 
treatment 
Total Days Total 
Days Results IP OP 
1. 2952 Kandasamy 37/M Coolie 3 Years 3.11.17 2.12.17 30 - 30 Good 
2. 3046 Lakshmi 58/F House Wife 2 Years 14.11.17 28.11.17 15 15 30 Fair 
3. 342 Sudalai 50/M Agricultural labour 3 Years 8.2.18 14.2.18 7 23 30 Fair 
4. 485 Sharmila 37/F Tailor 6 Months 22.2.18 12.3.18 19 11 30 Good 
5. 561 Ranjitham 60/F House Wife 7 Months 1.3.18 12.3.18 12 18 30 Good 
6. 628 Chella Thurai 60/M Business 2 Years 8.3.18 19.3.18 12 18 30 Fair 
7. 633 Uma Chanthiran 60/M Loadman 8 Months 8.3.18 14.3.18 7 23 30 Poor 
8. 631 Nata Rajan 60/M Driver 6 Years 8.3.18 14.3.18 7 23 30 Poor 
9. 630 Venkatesh 38/M Business 7 Years 8.3.18 19.3.18 12 18 30 Fair 
10. 629 Ravinthran 60/M Driver 3 Years 8.3.18 6.4.18 30 - 30 Good 
11. 624 Sankara Pandian 60/M Business 1 Year 8.3.18 6.4.18 30 - 30 Good 
12. 688 Isakkiammal 48/F House Wife 4 Years  13.3.18 29.3.18 17 13 30 Good 
13. 719 Hariharan 46/M Agricultural labour 2 Years 15.3.18 29.3.18 15 15 30 Fair 
14. 777 Krishnasamy 43/M Business 3 ½ Years 21.3.18 18.4.18 29 1 30 Good 
15. 965 Parvathi 45/F Agricultural labour 9 Months 10.4.18 9.5.18 30 - 30 Good 
16. 1135 Esakki 39/M Agricultural labour 2 Years 26.4.18 17.5.18 22 8 30 Good 
17. 1137 Suseela 47/F House Wife 1 Year 26.4.18 25.4.18 30 - 30 Good 
18. 1136 Velappan 49/M Tailor 2 Years 26.4.18 25.4.18 30 - 30 Good 
19. 1182 Suresh kumar 40/M Coolie 2 Months 1.5.18 30.5.18 30 - 30 Good 
20. 1200 Indhira 50/F House Wife 11 Months 3.5.18 1.6.18 30 - 30 Good 
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CHAPTER-VI 
 
DISCUSSION 
 
 
 Thandaga Vatham has described by Yugi Munivar in ‘Yugi Vaidhiya 
Chinthamani-800’ is nearly correlated in modern medicine is Lumbar Spondylosis.  
In this clinical trial study totally 40 patients were selected, 20 were treated as Out 
patients and 20 were treated as In patients with clinical trial drug ‘VAEPPAM 
PATTAI KUDINEER’ 50ml  twice a day.  The most important clinical features of 
Thandaga Vatham is pain in low back area, stiffness, restricted movements, 
tenderness, numbness and radiating pain.The diagnosis was made by Siddha and 
modern diagnostic tools. 
 
 Institutional ethiclal committee clearance was obtained for this study with IEC 
No.GSMC/3-IEC/2016-I-3/20.07.2016. 
 
 To evaluate the standardization of the trial drug, it is authenticated through 
visual inspection and organoleptic characters.  To ensure safety is made through vivo 
and vitro studies. 
 
 Professor, Associate Professor and Lecturers of the Department of Pothu 
Maruthuvam had supervised the entire clinical study, its observation and results. 
 
 The observed results were discussed below: 
 
1. Incidence with Age Distribution: 
 
The disease was found to be higher in the age group of 41-50 in both OP and 
IP (OP-40% & IP-65%)  
 
2. Incidence with Sex Distribution: 
 
 60% of the Out paitents were males and 40% were females. 
 65% of the In patients were males and 35% were females. 
 
3. Distribution according to Kaalam: 
 
Greater part of the cases belonged to Pitha Kaalam which is commonly the 
period of degeneration (OP-95% & IP-100%). 
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4. Distribution according to Paruva Kaalam: 
 
High incidence of the disease was in Munpani Kaalam with 45% in OP and 
Pinpani Kaalam with 60% in IP. 
 
5. Incidence with Thinai:  
 
Most of the cases were reported  from Marutham (OP-100% & IP-70%). 
 
6. Incidence with reference to Constitution of the Body: 
 
Vatha Thegi were much affected (OP-80% & IP-75%) 
 
7. Incidence with reference to Gunam: 
 
All cases had Rajo Gunam. 
 
8. Incidence with reference to Religion: 
 
The highest incidence was found to be among Hindus (OP-80% & IP 95%) 
 
9. Incidence with reference to Socio-Economic Status: 
 
In this clinical study most of the patients were from low income class with 
80% in IP and also from low income class with 70% in OP. 
 
10. Incidence with reference to Food Habit: 
 
Most of the patients belonged to non-vegeterian (OP-90% & IP-70%). 
 
11. Incidence with reference to Family History: 
 
Most of the patients don’t have family history related to this disease (OP-85% 
& IP-85%). 
 
12. Incidence with reference to Occupation: 
 
Most of the patients strained themselves as heavy workers, lifting heavy 
weight, travelling a long distance and sitting for a long period of time.  These may be 
the reasons to develop Thandaga Vatham. 
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13. Incidence with reference to Aetiological Factors: 
 
Age, obesity and occupation were the main precipitating factors in majority of 
cases. 
 
14. Incidence with reference to Mode of Onset: 
 
Most of the patients were observed in chronic state (OP-100% & IP-100%). 
 
15. Incidence with Duration of Illness: 
 
Majority of the cases were observed above 12 months of duration (OP-70% & 
IP-60%). 
 
16. Incidence with Clinical Manifestation: 
 
100% of both OP & IP had low back pain and exacerbation of pain on 
movements. Radiating pain to lower limbs, restricted movements, stiffness, 
tenderness and numbness were present in variable number among the patients under 
study. 
 
17. Incidence with reference to Kanmenthiriyam: 
 
 Kaal was affected among 85% of OP & 100% of IP.  
 
18. Incidence with reference to Gnanendrium: 
 
 Mei (Local heat) was affected among 25% of OP and 35% of IP.   
 
19. Incidence with reference to Kosam: 
 
 Vinganamaya Kosam (Restriction of movements, low back pain) was 
affected in all cases.   
 Annamaya Kosam (Anorexia )was affected among 30% of OP & 25% of IP. 
 
20. Condition of Mukkutram: 
 
a). Disturbance in Vatham: 
 
 Koorman was affected among 10% of OP. 
 Kirukaran (Secretion of saliva) was affected among 10% of OP and 25% 
of IP. 
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 Viyaanan (Movements, nervous functions and sensation), Samaanan 
(Regulates the digestion and controls all the other vayus) and Devathathan 
(Laziness) were affected in all cases.  
 Abaanan (Constipation) was affected among 35% of OP and 25% of IP. 
 
b). Disturbance in Pitham: 
 
 Sathagam (Wilful activities) was affected in all cases.   
 Analagam (Digestion) was affected among 30% of OP and 25% of IP. 
 Ranjagam (Nutrition to blood) was affected among 25% of OP and 10% of 
IP. 
 
c). Disturbance in Kapham: 
 
 Santhigam (Integrity of joints) was affected in all cases. 
 Klethagam (Lubrication of food) was affected among 30% of OP and 25% 
of IP. 
 
21. Incidence with reference to Udal Thathukkal: 
 
Saaram, Kozhuppu, Enbu were affected in all cases. Senner was affected 
among25% of OP and 10% of IP. Disturbance in Saaram produce symptoms like 
lethargy and mental depression. Disturbance in senner was associated with Anemia.  
Disturbance in Kozhuppu, Enbu produce restricted movements, reduced intervertebral 
disc space, extra osteophyticchanges and degenerative spondylotic changes in Lumbar 
Vertebrae. 
 
22. Incidence with reference to Envagai Thervugal: 
 
 In this study all cases had thontha naadi with high incidence of Vatha 
Pitham (OP-55% & IP-60%). 
 Sparisam was affected among 25% of OP and 30% of IP.  
 Vizhi was affected among 35% of OP & 10% of IP. 
 Malam was affected among 35% of OP & 25% of IP. 
 
23. Incidence with reference to Neer Kuri: 
 
 Niram was affected among 30% of OP & 35% of IP. 
24. Incidence with reference to Neikuri: 
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Majority of cases showed the neikuri as spreading like snake, when the oil is 
dropped into the urine indicating the predominance of Vatha neer (OP-90% & IP-
85%). 
 
25. Incidence with reference to Radiological Studies: 
 
From the X-Ray of Lumbar spine (AP & Lateral view) all the cases had 
degenerative spondylotic changes. Reduced intervertebral disc space found among 
10% of OP and 15% of IP. After treatment no changes is noted in X-Rays. 
 
26 (a) Assessment of Outcome - Back pain functional scale score. 
 
After treatment65% of OP and 70% of IP had good improvement.  25% of OP 
and 20% of IP had moderate improvement.10% of OP and IP had mild improvement. 
 
27. Incidence with reference to results: 
 
 65% of OP and 70% of IP had good response. 
 25% of OP and 20% of IP had moderate response. 
 10% of both OP & IP had poor response. 
 It was found that the end of result showed good clinical improvement in 
grade with reduction of low back pain, numbness, stiffness, radiating pain, 
tenderness and restricted movements.  
 
The statistical analysis of the observational parameters clearly indicates that 
Vaeppam Pattai Kudineer is highly siginificant in the treatment of Thandaga Vatham. 
 
Biochemical analysis of VAEPPAM PATTAI KUDINEER showed the 
presence of sulphate, starch, ferrous iron, amino acid, unsaturated compound and 
reducing sugar. 
 
Acute oral toxicity of VAEPPAM PATTAI KUDINEER given to albino mice 
did not produce toxicities. 
 
Thus VAEPPAM PATTAI  KUDINEER by virtue of its actions mentioned 
previously help in reducing the cardinal signs of lumbar spondylosis and prevents 
further degeneration. 
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CHAPTER-VII 
 
SUMMARY 
 
 
 An open labelled randomized clinical study on “THANDAGA VATHAM” 
with reference to its aetiology, pathogenesis, clinical features, diagnosis, 
investigations and treatment were conducted at Department of Pothu Maruthuvam, 
Government Siddha Medical CollegeHospital, Palayamkottai. 
 
This clinical study of Thandaga Vatham is done on the basis of reference in 
Yugi Vaidhya Chinthamani-800, which is correlated with Lumbar Spondylosis.  
 
The trial drug chosen for the clinical study is ‘VAEPPAM PATTAI 
KUDINEER’. Dosage 50ml twice daily after food for 30 days (Ref: Gunapadam 
Mooligai Vagupu, Page No.859). 
 
A number of literatures were collected regarding Siddha as well as modern 
system of medicine. 
 
For this study, out of 40 patients, 20 patients were diagnosed clinically and 
admitted in the In patients ward and treated with trial medicines. Another 20 as Out 
patients. 
 
The selection and management of patients during admission and after 
treatment is carried out under the supervision of Professor, Associate Professor, 
Lecturers of Department of Pothu Maruthuvam. 
 
A log book and a case sheet proformais prepared with particulars focussed on 
Siddha and Modern clinical parameters. 
 
Separate case sheets were maintained for each patient in In patient ward and 
their vital signs and symptoms were monitored and recorded daily. The patient treated 
with the trial drug VAEPPAM PATTAI KUDINEER twice a day daily. 
 
In case of Out patients, the trial drug this made into packets of 7 grms. 4 such 
packets are given and the method of preparing infusion is instructed.  They have 
93 
 
visited the hospital once in two days. At each visit clinical assessment and prognosis 
were noted.  
 
Routine blood examinations, urine analysis, specific investigations and 
radiological investigations were done by scientific methods and were considered for 
diagnosis and progress of the patients.  
 
Siddha diagnosis is achieved with the help of Envagai Thervugal and Ezhu 
Udal Thathukkal. 
 
Since Thandaga Vatham is a chronic disease, it requires treatement for 
minimum thirty days to minimize severe pain, tenderness, swelling and stiffness 
further the patient is advised to follow up the treatment in Out patients department. 
 
From this study the following datas are clear that the disease was more 
common in males then femals. The disease has increased incidence among individuals 
with more physical activity, higher BMI scores.  Despite marked variability within the 
population, men appear to have more significant degenerative changes than women.  
Maximum incidence was in Pitha Kaalam.  Clinically marked reduction in the 
symptoms along with increase sense of well being, improvement in the grade of 
cardinal signs and range of motion, decrease in the “BACK PAIN FUNCTIONAL 
ASSESSMENT SCORE” was noted.  
 
The patients were observed for a period of 3 months during and after the 
course of treatment.  No signs of complications were reported.  Clinically no toxic 
effects were noticed during the treatment period. The Pharmacological evaluation and 
biochemical analysis of VAEPPAM PATTAI KUDINEER were also carried out.  
 
Results of this clinical trial study statistically proved significant. 
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CHAPTER-VIII 
 
CONCLUSION 
 
 
 Thandaga Vatham mentioned in Yugi Vaidhya Chinthamani-800 which is 
correlated with the clinical conditions as Lumbar spondylosis is a greatest hazard to 
the world.  The people suffering from lumbar spondylosis goes on increasing day by 
day even at the age of 20.  This is a wear and tear mechanism that people could not 
stop to take relaxment in their time clock until some mechanical stress and pain 
happens.  So a treatment is essential for them inspite of their work to cure the disease. 
 
 The disease ‘Thandaga Vatham’ is treated with Vaeppam Pattai Kudineer 
and is well analysed under Siddha and modern parameters.  The cases were 
thoroughly examined with clinical and biochemical report. 
 
 Of the total 40 patients, 67.5% showed good response; 22.5% showed 
moderate response; 10%  showed  poor  response.  Thus, I conclude that mankind has 
got a better remedy. I hope this trial drug ‘VAEPPAM PATTAI KUDINEER’ would 
add a feather to the glory of Siddha system and brings it to a new leap on forth 
coming research. 
 
 Ntg;gk;gl;il FbePhpy; NrUk; ruf;Ffs; ; ; ; P ; ; ; ;; ; ; P ; ; ; ;; ; ; P ; ; ; ;  
         
Ntg;gk;gl;il                           jpg;gpyp   
 
 
 
 
Ntg;gk;gl;il FbePH 
 
  
 BEFORE TREATMENT 
Name : SHARMILA    IP NO : 485    Age/Sex : 37Y/F 
 
 
 
 
AFTER TREATMENT 
Name : SHARMILA    IP NO : 485    Age/Sex : 38Y/F 
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ANNEXURE – I 
PREPARATION AND PROPERTIES OF TRIAL MEDICINE 
Ntg;gk; gl;ilf; FbePH; ; ; ; P; ; ; ; P; ; ; ; P  
(Reference: Gunapadam Mooligai Part-I, Page No:859) 
Ntg;gk; gl;il 4 fpuhk;> jpg;gpyp 8 fpuhk; NrHe;j FbePiu ,Lg;G thjk;> 
fPy;thjj;jpw;F toq;fptu> ew;gad; nfhLf;Fk;. 
1. Drug Name   :  Vaeppam Pattai 
Botanical Name  :  Azadirachta indica 
Family   :  Meliaceae 
Part used   :  Bark 
Phyto chemicals :  Nimbidal, Nimbidin, Gedunin 
Action :  Anti-inflammatory, Anti-arthritic, Anti-pyretic,  
Analgesic, Immuno-stimulant, Astringent, Demulcent. 
Therapeutic uses :  Vatha diseases, hyperdipsia, leprosy, skin diseases,  
eczema, leucoderma, pruritis, intermittent and malarial 
fevers, wounds, ulcers, burning sensation, tumour, 
anorexia, vomiting, inflammation, syphilis. 
2. Drug Name   : Thippili 
Botanical Name  :  Piper longum 
Family   :  Piperaceae 
Part used   :  Dried spike 
Phyto chemicals :  Resin, Volatile, Starch, Fatty acid, Piperine. 
Actions :  Analgesic, Anti-inflammatory, Sedative, Tonic,  
Carminative, Vermifuge, Emmenagogue. 
Therapeutic uses :  Bronchial asthma, insomnia, jaundice, viral hepatitis,  
rheumatism, cough, bronchitis, muscular pains, 
inflammation, dysentry, leprosy.  
Dose   :  50 ml – twice a day  
Duration  :  30 days 
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METHOD OF PREPARATION: 
 The purified drug is coarsely pounded. For the preparation of decoction 25 grams of 
the powder is boiled and made kasayam for dispensing to patients. 
 
Ntg;gk; gl;il: ; ; ;; ; ;; ; ;  
 Rit   :  ifg;G> rpW JtHg;G 
 jd;ik  :  ntg;gk; 
 gphpT   :  fhHg;G 
 
jpg;gpyp:;;;  
 Rit   :  ,dpg;G 
 jd;ik  :  ntg;gk; 
 gphpT   : ,dpg;G 
 
PURIFICATION OF DRUGS: 
Vaeppam Pattai : 
 Removes the adulterant and make it dried on the shade light. 
Thippili : 
 Soak in lime juice and make it dry. 
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ANNEXURE- II 
BIO CHEMICAL ANALYSIS OF “VAEPPAM PATTAI KUDINEER” 
Preparation of the extract: 
 
5gms of the drug was weighed accurately and placed in a 250 ml clean beaker then 50 ml 
of distilled water is added and dissolved well. Then it is boiled well for above 10 minutes. It 
is cooled and filtered in a 100 ml volumetric flask and then it is made to 100 ml with distilled 
water this fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S. 
NO. 
EXPERIMENTS OBSERVATION INFERENCE 
1. Test For Calcium: 
    2ml of the above prepared extract 
taken in a clean test tube. To this add 
2ml of 4% Ammonium oxalate 
solution. 
 
No white precipitate is 
formed. 
 
Absence of 
 Calcium. 
2. Test For Sulphate: 
   2ml of the extract is added to 5% 
Barium Chloride Solution.  
 
A white precipitate is 
formed. 
 
Indicates the 
presence of 
sulphate. 
3. Test For Chloride: 
   The extract is treated with silver 
nitrate solution. 
 
No white precipitate is 
formed. 
 
Absence of 
chloride. 
 
4. Test For Carbonate: 
  The substance is treated with 
concentrated Hcl. 
 
No brisk effervescence is 
formed. 
 
Absence of 
carbonate. 
5. Test For Starch: 
The extract is added with weak iodine 
solution. 
 
Blue colour is formed. 
 
Indicates the 
presence of starch. 
6. Test For Ferric Iron: 
The extract is acidified with Glacial 
acetic acid and potassium ferro 
cyanide. 
 
No Blue colour is formed. 
 
Absence of ferric 
iron. 
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INFERENCE 
 Indicates the presence of sulphate, starch, ferrous iron, amino acid, unsaturated 
compound and reducing sugar. 
7. Test For Ferrous Iron:  
The extract is treated with 
concentrated nitric acid and 
Ammonium thiocyanate solution. 
 
Blood red colour is 
formed. 
 
Indicates the 
presence of ferrous 
iron. 
8. Test For Phosphate: 
 The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid. 
 
No yellow precipitate is 
formed 
 
Absence of 
phosphate 
9. Test For Albumin: 
The extract is treated with Esbach’s 
reagent. 
 
No yellow precipitate is 
formed. 
 
Absence of 
Albumin. 
10. Test For Tannic Acid: 
 The extract is treated with ferric 
chloride. 
 
No blue black precipitate 
is formed. 
 
Absence of Tannic 
acid. 
11. Test For Unsaturation: 
Potassium permanganate solution is 
added to the extract. 
 
It gets decolorized. 
Indicates the 
presence of 
unsaturated 
compound. 
12. Test For The Reducing Sugar: 
5ml Of Benedict’s qualitative solution 
is taken in a test tube and allowed to 
boil for 2 minutes and add 8 to 10 
drops of the extract and again boil it 
for 2 minutes 
 
Colour change occurs. 
 
Indicates the 
presence of 
reducing Sugar. 
13. Test For Amino Acid: 
One or two drops of the extract is 
placed on a filter paper and dried well. 
After drying, 1% Ninhydrin is sprayed 
over the same and dried it Well. 
 
Violet colour is formed. 
 
Indicates the 
presence of Amino 
acid. 
14. Test For Zinc: 
The extract is treated with Potassium 
Ferro cyanide. 
 
No white precipitate is 
formed. 
 
Absence of Zinc. 
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ANNEXURE – III 
PHARMACOLOGICAL ANALYSIS 
ANALGESIC ACTIVITY OF SIDDHA FORMULATION OF         
VAEPPAM PATTAI KUDINEER 
ANALGESIC ACTIVITY 
             Analgesic activity of siddha formulation Vaeppam Pattai Kudineer was evaluated 
by acetic acid induced writhing reflux in mice. Painful reaction in animals may be 
produced by the chemicals such as phenylquinone, bradykinin etc.  Like that, acetic acid 
pain reaction which is characterized as a writhing response. Construction of abdomen, 
turning of trunk (twist) and extension of hind legs are taken as reaction to chemically 
induced pain. Analgesics (both narcotic and non-narcotic) inhibit writhing response. 
REQUIREMENTS: 
Animal                                : Swiss albino mice (20-25g) either sex 
Drugs and chemicals          : Diclofenac sodium (standard), 
                                              Acetic acid (1%v/v), Vaeppam Pattai Kudineer                                            
METHOD: 
TREATMENT PROTOCOL 
Group-1     Treated as normal control received 10ml/kg of normal saline through orally. 
Group-2     Treated as Standard control received 10mg/kg of diclofenac sodium through                 
                   Intraperitonealy. 
Group-3    Treated as treatment control received 100mg/kg of Vaeppam Pattai Kudineer 
administered through orally.                         
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Group-4    Treated as treatment control received 200mg/kg of Vaeppam Pattai Kudineer 
administered through orally.                           
                         Siddha formulation Vaeppam Pattai Kudineer was administered one 
hour prior to the acetic acid administration. Note the onset on writhing. Record the 
numbers of abdominal contractions, trunk twist and extension of hind limbs as well as the 
number of animals showing such response during a period of 10 minutes were noted. 
 STATISTICS: 
          Data are expressed as mean ± SEM; data analyzed by one way ANOVA 
followed by Newman’s keul’s multiple range tests to determine the significance of the 
difference between the control group and rats treated with the extracts. 
  *   Values were considered significant at P< 0.01. 
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TABLE No.1 
ANALGESIC ACTIVITY OF VAEPPAM PATTAI KUDINEER BY ACETIC 
ACID INDUCED WRITHING REFLUX IN MICE 
Treatment Dose (mg/kg) No. of writhing 
% reduction in 
reaction time 
Group I 
Normal saline 
Inject 1%v/v acetic 
acid 1ml/100g of 
body weight 
48.9±2.65 - 
Group II 
Std 
10mg/kg  
I.P.Diclofenac 
sodium 
        15.6±0.76 68.09%** 
Group III 
Vaeppam Pattai 
Kudineer 
100mg/kg 
Administered 
through orally. 
22.6±1.48 53.78%** 
Group IV 
Vaeppam Pattai 
Kudineer 
200mg/kg 
Administered 
through orally  
20.3±1.20 58.48%** 
 
Values are expressed as mean±SEM 
Values were find out by using one-way ANOVA followed by Newman’s keuls multiple 
range tests. 
**   Values were considered significant at P< 0.01. 
RESULTS: 
The table values show that analgesic activity of Vaeppam Pattai Kudineer by 
acetic acid induced writhing reflex. The results reveals that both dose of Vaeppam Pattai 
Kudineer possess significant analgesic activity at p<0.01.  
viii 
 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION 
VAEPPAM PATTAI KUDINEER 
  The anti-inflammatory activities of siddha formulation Vaeppam Pattai Kudineer 
at a dose of 100 and 200mg/kg were evaluated using carrageenan-induced paw edema 
method. The inflammation was readily produced in the form of edema with the help of 
irritant such as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea 
weed (Rhodophyceae) and when injected cause the release of prostaglandins by the way 
it produces inflammation and edema. 
REQUIREMENTS: 
Animal                                :  Albino rat (180-200 g) 
Drugs and chemicals          :  Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
Digital plethysmo meter. U G O Basile (Italy) 
Test compounds                :    Siddha formulation Vaeppam Pattai Kudineer 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of Bhandri 
et al(1) The animals were divided into 4 groups each having six animals. A freshly 
prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the planter region 
of left hind paw of each rat. One group was kept as control and the animals of the other 
groups were pretreated with the siddha formulation Vaeppam Pattai Kudineer  test 
Compounds dissolved with 2 ml sterile water given through orally 30 min before the 
carrageenan treatment. The paw volumes of the test compounds, standard and control 
groups were measured at 60,240,360 minutes of carrageenan treatment with the help of 
Digital plethysmometer (Ugo basile, Italy). Mean increase in paw volume was measured 
and the percentage of inhibition was calculated. 
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% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION VAEPPAM 
PATTAI KUDINEER 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 10ml/kg orally 5.58±0.93 - 
Group II 
   Std 
10mg/kg 
Diclofenac sodium 
I.P. 
1.74±0.41 68.81%*a 
Group III 
Vaeppam Pattai 
Kudineer 
100mg/kg.Orally. 2.08±0.52 62.72%*a 
Group IV 
Vaeppam Pattai 
Kudineer 
200mg/kg.Orally.  1.97±0.45 64.69%*a 
 
* Data are expressed as Mean ± S.E.M. 
* Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple range 
tests, to determine the significance of the difference between the control group and rats 
treated with the test compounds. 
* Data values were significantly different from normal control at P< 0.01. 
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Results: 
Anti- inflammatory activity 
  Both doses of siddha formulation Vaeppam Pattai Kudineer at 100mg/kg and 
200mg/kg were tested for their Anti- inflammatory activity by using carrageenan Induced 
rat paw edema method and the results are tabulated in table no 1.  The results reveals that   
both doses of siddha formulation Vaeppam Pattai Kudineer at 100mg/kg and 200mg/kg 
doses possesses significant Anti- inflammatory activity when compared to control group 
at p<0.01. 
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ANNEXURE – IV 
ACUTE TOXICITY STUDY 
 
Acute toxicity study of Vaeppam Pattai Kudineer : 
Determination of acute oral toxicity is usually the initial screening step in the 
assessment and evaluation of the toxic characteristics of all compounds. The types of 
toxicity tests which are routinely performed by pharmaceutical manufacturers in the 
investigation of a new drug involve acute, sub-acute and chronic toxicity. Acute 
toxicity is involved in estimation of LD50 (the dose which has proved to be lethal 
(causing death) to 50% of the tested group of animals) 
 (Shetty Akhila, et al., 2007).(1) 
Method:Acute oral toxicity of Vaeppam pattai kudineer is carried out as per the 
guidelines Organization of Economic Co-operation and Development (OECD) -423 
guidelines after the animal ethical clearance from Institutional Animal Ethics 
Committee.  
The albino mice are fasted over night and provided only water, after which the 
Vaeppam Pattai kudineer is administered by gastric intubations to the relevant 
group of animals orally at the dose of 50 mg.kg-1 body weight in Tween-80. The 
animals are then observed for 14 days and maintained with normal food. A mortality 
rate of 2 or 3 animals in 14 days is recorded and the dose is said to be toxic dose. But 
when mortality of one animal is observed, then the same dose is repeated again for 
confirmation. However, if mortality is not observed, the procedure is repeated for 
further higher doses such as 300 and 2,000 mg.kg-1 body weight. Toxic symptoms are 
observed for 72 hrs including behavioral changes, locomotion, convulsions and 
mortality (Shah Ayub, 1997, Bürger, 2005).(2,3). 
Cage Side Observations: 
 Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Special attention is directed for the 
observation of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma. 
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Body Weight, Food and Water Intake: 
 Body weight, food and water intake are recorded at two-day intervals.  
Pathology: 
 Surviving animals are fasted overnight, weighed and humanely killed on the 
15th day using anesthetic ether. All test animals are subjected to gross necropsy. 
Subchronic test for Vaeppam Pattai Kudineer : 
This experiment evaluates the toxicity potential of Vaeppam Pattai Kudineer. 
Method: Male and female Wistar rats weighing 180 ± 10 g are used for the present 
study. The animals are divided into five groups of six animals each. The dose of the 
preparation is calculated based on the body weight of the animal.   The animals in 
Group I are administered with a single daily dose of 0.5 ml of Tween 80 orally for 20 
days. The animals in Group II are administered with 50 mg.kg-1b.w. of the Vaeppam 
Pattai Kudineer orally once daily for 20 days. The animals in Group III are 
administered with 100 mg.kg-1b.w. of the Vaeppam pattai kudineer orally once daily 
for 20 days. The animals in Group IV and V are administered once daily with 200 and 
400 mg.kg-1b.w. of the Vaeppam pattai kudineer respectively for 20 days orally 
(Pieme,et al 2006, Joshi, et al 2007, Mythilypriya, et al., 2007).(4,5,6)The animals are 
then weighed every five days, from the start of the treatment, to record the weight 
variation. At the end of the treatment, blood samples are collected by puncturing retro 
orbital plexus after mild anesthesia for biochemical analysis. The collected blood 
sample is centrifuged within 5 min of collection at 4000 g for 10 min to obtain 
plasma, which is analyzed for total cholesterol, total triglyceride, HDL-cholesterol 
levels,LDL-cholesterol,plasma glucose, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), creatinine and urea. 
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Results: 
Acute toxicity study with Vaeppam pattai kudineer: 
 The acute toxicity of Vaeppam pattai kudineer was evaluated using OECD- 
423 guidelines. There was no mortality or morbidity observed in animals through the 
15-days period following single oral administration at all selected dose levels of the 
Vaeppam pattai kudineer (Table-1).   The animals did not show any changes in the 
general appearance during the observation period. Morphological characteristics such 
as fur, skin, eyes and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual behaviors such as self mutilation, walking backward and 
so forth were observed.   Gait and posture, reactivity to handling or sensory stimuli, 
grip strength was also normal.  
 Dose (mg.kg-1) Sign of Toxicity 
(ST.NB-1) 
Mortality (D.S-1) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            3/3 
Table.1. Acute toxicity study of Vaeppam pattai kudineer on experimental mice. The 
acute toxicityof Vaeppam pattai kudineer on experimental mice was tested using 
OECD-423 guidelines, where ST- sign of toxicity; NB- normal behaviour; D- died; S- 
survive.  Values are expressed as number of animals (n=3). 
Effect of Vaeppam pattai kudineer inSubchronic Toxicity : 
Vaeppam pattai kudineer were evaluated for subchronic toxicity. 
Effect of Vaeppam pattai kudineer on body weight changes in rats: 
The effect of Vaeppam pattai kudineer was observed for their effect on the body 
weight changes from the study it was observed that, there was significant increase 
(p<0.05) in body weight in all the animals observed.   The results are shown in 
Table.2. 
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Treatment Day 1 Day 5 Day 10 Day 20 
Control 184.19±5.43 185.40  ±6.12 194.10 ±6.30 194.6±6.28 
Vaeppam pattai kudineer 
 50 mg.kg-1 
191.34 ±6.23 194.30  ±6.44 195.48 ±6.75 195.30±6.82* 
Vaeppam pattai kudineer 
100 mg.kg-1 
184.36 ±6.03 191.43  ±6.42 193.30  ±6.54 195.84±6.68* 
Vaeppam pattai kudineer 
200 mg.kg-1 
193.25  ±7.03 195.20±6.34 195.48  ±6.58** 203.35±6.70** 
Vaeppam pattai kudineer 
400 mg.kg-1 
184.54  ±6.37 191.35  ±6.65 193.15  ±6.65** 201.52±6.72** 
 
Table.2.The effects of Vaeppam pattai kudineer on body weight changes in rats.   A 
study on the effects of Vaeppam pattai kudineer on body weight changes in rats was 
carried out.. where, group I animals (GPI) were treated with normal saline (5 ml.kg-1), 
group II animals (GPII) with 50 mg.kg-1 of Vaeppam pattai kudineer,  group III 
animals (GPIII)  with 100 mg.kg-1 of Vaeppam pattai kudineer, group IV animals 
(GPIV)  with 200 mg.kg-1 of Vaeppam pattai kudineer, group V animals (GPV)  
with 400 mg.kg-1Vaeppam pattai kudineer. The values are expressed as mean ± 
S.E.M. n=6. The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Effect of Vaeppam pattai kudineer on kidney,heart, liver and brain 
in rats: 
The effects of Vaeppam pattai kudineer on kidney, heart, liver and brain of the rats 
were observed. From the study it was clear that, significant (p<0.01) changes in the 
weights of various organs of the animals occurred with higher doses of the extract 
(400 mg.kg-1bwt), but macroscopic examinations did not show any changes in colour 
of the organs of the treated animals compared with the control.   The results are 
shown in Table.3. 
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Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.39 ± 0.04 0.79± 0.03 3.27± 0.14 0.69± 0.05 
Vaeppam pattai 
kudineer@50 mg.kg-1 
0.41± 0.05 0.87± 0.05 3.37± 0.19 0.67± 0.03 
Vaeppam pattai 
kudineer@100 mg.kg-1 
0.44± 0.06 0.87± 0.04 3.39±0.21 0.65± 0.08 
Vaeppam pattai 
kudineer@ 200 mg.kg-1 
0.39± 0.03 0.80± 0.02 3.31± 0.22 0.73± 0.09 
Vaeppam pattai 
kudineer@400 mg.kg-1 
0.42± 0.05 0.79± 0.02 3.33± 0.15 0.72± 0.12 
Table.3.The effects of Vaeppam pattai kudineer on kidney, heart, liver and brain of 
the rats. A study on the effects of Vaeppam pattai kudineer on kidney, heart, liver 
and brain of the rats was tested. where, group I animals (GPI) treated with normal 
saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of Vaeppam pattai 
kudineer,  group III animals (GPIII)   with 100 mg.kg-1 of Vaeppam pattai 
kudineer, group IV animals (GPIV)   with 200 mg.kg-1 of Vaeppam pattai 
kudineer, group V animals (GPV)  with 400 mg.kg-1Vaeppam pattai kudineer.  The 
values are expressed as mean ± S.E.M. n=6.   The results of group I were compared 
with other groups such as II, III, IV,  and V.  The statistical analysis was carried out 
using one way ANOVA method, where **P<0.01. 
Effect of Vaeppam pattai kudineer on biochemical profiles of rats:   
The effect of Vaeppam pattai kudineer on various biochemical parameters of the 
experimental animal ‘rats’ were tested.From the study it was evident that, there was 
significant decrease (p<0.05) in the plasma glucose level in treated rats especially at 
higher dose (400 mg.kg-1) compared with control rats.   The control rats were 
administered only with 5 ml of normal saline.   Significant decrease (p<0.05) in the 
plasma total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were 
observed.   But a significant increase (p<0.05) in HDL-cholesterol levels were 
observed in all the treated animals compared with the control animals. AST, ALT and 
ALP levels were also normal in the Vaeppam pattai kudineer treated animals.  
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From the results of biochemical study there was no evidence of severe toxicity 
associated with the administration of higher concentration of Vaeppam pattai 
kudineer. The results are shown in Table.4. 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 94.42±1.74 29.05± 0.62 28.25±1.43 138.45±3.15 85.28±1.83 
Vaeppam pattai 
kudineer@ 50 
mg.kg-1 
93.50±1.62 25.30± 0.36* 11.36± 0.85* 176.40±3.65* 70.77±1.36 
Vaeppam pattai 
kudineer@ 100 
mg.kg-1 
91.44±1.52 23.65± 0.30* 13.32± 0.90* 165.30±3.40* 69.56±1.28 
Vaeppam pattai 
kudineer@ 200 
mg.kg-1 
89.30±1.35** 24.20± 0.38 15.40± 0.92* 184.34±3.70* 46.54±1.16 
Vaeppam pattai 
kudineer@ 400 
mg.kg-1 
92.28±1.43** 30.45± 0.48 18.30±1.15* 182.24±3.66* 45.32±1.03 
 
 
Table.4. The effect of Vaeppam pattai kudineer on biochemical parameters such as 
glucose, cholesterol, triglyceride, HDL and LDL. A study on the  effect of Vaeppam 
pattai kudineer on biochemical parameters such as glucose, cholesterol, triglyceride, 
HDL and LDL in rats was tested.where, group I animals (GPI) treated with normal 
saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of Vaeppam pattai 
kudineer,  group III animals (GPIII)  with 100 mg.kg-1 of Vaeppam pattai kudineer, 
group IV animals (GPIV)  with 200 mg.kg-1 of, group V animals (GPV)   with 400 
mg.kg-1Vaeppam pattai kudineer. The values are expressed as mean ± S.E.M. n=6.   
The results of group I were compared with other groups such as II, III, IV, and V.  
The statistical analysis was carried out using one way ANOVA method, where 
**P<0.01 *P<0.05 
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Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMI
N 
(g.l-1) 
Control 335.3±11.6
0 
80.4± 3.42 260.35± 8.57 78.36± 3.31 48.30±2.4
4 
Vaeppam pattai 
kudineer@50 
mg.kg-1 
325.4±10.5
2** 
78.3± 2.90** 272.15±8.74** 78.30±3.20 45.24±2.2
9 
Vaeppam pattai 
kudineer@ 100 
mg.kg-1 
324.5±10.6
0** 
75.3±2.92** 273.38±8.27** 88.12±3.80 46.30±2.4
4 
Vaeppam pattai 
kudineer@ 200 
mg.kg-1 
323.5±9.90 72.3± 2.38 273.20±8.33 79.35± 3.65 47.28±2.4
5 
Vaeppam pattai 
kudineer@ 400 
mg.kg-1 
325.4±9.94 72.6±2.45 273.42±8.41 79.30± 3.75 47.64±2.4
9 
 
Table.5. The effects of Vaeppam pattai kudineer on biochemical parameters such 
as AST, ALT, ALP, TP and Albumin in rats. A study on the effects of Vaeppam 
pattai kudineer on biochemical parameters such as AST, ALT, ALP, TP and 
Albumin rats was tested. where, group I animals (GPI)  were treated with normal 
saline (5ml.kg-1),  group II animals (GPII) with 50 mg.kg-1 of HAEBD group III 
animals (GPIII)  with 100 mg.kg-1 of Vaeppam pattai kudineer, group IV animals 
(GPIV)  with 200 mg.kg-1 of Vaeppam pattai kudineer,  and group V animals (GPV)  
with 400 mg.kg-1Vaeppam pattai kudineer The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
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Effect of Vaeppam pattai kudineer on haematological parameters in 
rats :  
The effects of Vaeppam pattai kudineer were observed for its effect on 
haematological parameters on the experimental rats. From the study it was evident 
that, a significant increase (p<0.01) were observed in the haemoglobin contents and  
RBC count  in the group treated with 200 mg.kg-1 body weight of Vaeppam pattai 
kudineer and a significant decrease of the parameters occurred in the group treated 
with 400 mg.kg-1 b.w.t compared with the control.   There was no significant change 
in the calcium level in all the treated animals compared to the control. 
Treatment 
Haemoglobin 
(mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 18.53±1.28 9.32± 0.93 11.59± 0.90  9.48 ±0.60 
Vaeppam pattai 
kudineer@ 50 
mg.kg-1 
19.37±1.35* 9.40±1.05*   9.38± 0.82*  9.30 ±0.38 
Vaeppam pattai 
kudineer@ 100 
mg.kg-1 
19.22±1.84* 9.53±1.20*   8.37± 0.28*  9.32 ±0.45 
Vaeppam pattai 
kudineer@ 200 
mg.kg-1 
18.25±1.25* 8.42± 0.85* 11.61± 0.83*  9.60 ±0.56 
Vaeppam pattai 
kudineer@ 400 
mg.kg-1 
18.21±1.23* 8.51± 0.92*   10.88±0.75*  9.69 ±0.64 
Table.6. The effect of Vaeppam pattai kudineer on haematological parameters such 
as HB, Calcium, RBC and WBC in rats. A study on the effect of Vaeppam pattai 
kudineer on haematological parameters such as Hb, RBC, WBC, Calcium in rats was 
tested. where, group I animals (GPI) treated with normal saline (5 ml.kg1), group II 
animals (GPII)  with 50 mg.kg-1 of Vaeppam pattai kudineer,  group III animals 
(GPIII)   with 100 mg.kg-1 of Vaeppam pattai kudineer,   group IV animals (GPIV)   
with 200 mg.kg-1 of Vaeppam pattai kudineer, and  group V animals (GPV)  with 
400 mg.kg-1Vaeppam pattai kudineer. 
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The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV and V.   The statistical analysis was 
carried out using one way ANOVA method, where *P<0.05. 
 
Discussion: 
The evaluation of sub-chronic and chronic dosing in experimental animals 
may be more relevant in determining the overall toxicity of the plant preparation.  The 
highest overall concordance of toxicity in animals in comparison with humans is with 
hematological, gastrointestinal, and cardiovascular adverse effects whiles certain 
adverse effects in humans, especially hypersensitivity and idiosyncratic reactions, are 
poorly correlated with toxicity observed in animals (Olson, et al., 2000).(7) 
In the present study, where the acute toxicity study of Vaeppam pattai 
kudineer was carried out as per OECD-423 guidelines, no mortality was observed in 
both the animals of control group as well as animals treated with a maximum dose of 
2000 mg.kg-1.   Hence, 1/10th of 2000 mg.kg-1 i.e. 200 mg.kg-1 of dose was selected as 
a minimum dose for sub-acutetoxicity study (Abu TahaNael, et al., 2008).(8) 
The results of sub-acute toxicity study shows that there was no significant 
change in animal behaviour due to the absence of toxicity.   The animals treated with 
Vaeppam pattai kudineer showed normal growth pattern and body weight compared 
with control rats treated with normal saline. So the changes in body weight can be 
used as an indicator of adverse effects of drugs and chemicals (Tofovic and Jackson, 
1999; Raza, et al., 2002; Teo, 2002).(9,10,11)  
The changes in enzymes like ALP, AST and ALT levels show liver 
impairment, due to toxicity (Hayes, 1989).(12)   Serum cholesterol and proteins 
mainly regulated via synthesis in the liver and increase or decrease in serum 
concentrations of constituents suggest liver toxicity.   The results of the present study 
were assessed after 28 days of administration of Vaeppam pattai kudineer, and it 
was found that Vaeppam pattai kudineer at all concentrations do not produce liver 
damage.  
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There was a slight decrease in plasma glucose level, when higher doses of 
Vaeppam pattai kudineer (400 mg.kg-1) were administered in the treated rats. 
Analysis of blood parameters is likely to risk evaluation as the change in 
hematological system has a higher predictive value for human toxicity, when data are 
translated from animal studies (Olson, et al., 2000).(7)   After 28 days of treatment, 
there were no significant changes in the haematological parameters between control 
and treated groups.   No significant changes in the levels of WBC, RBC were 
observed between control and test groups following repeated administration of 
Vaeppam pattai kudineer. Interestingly, significant increase in the levels of 
hemoglobin was found in treatment with Vaeppam pattai kudineer with a higher 
dose of 400 mg.kg-1.   The possible reason could be that one of the constituents 
Vaeppam pattai kudineer may increase absorption of iron.  
The overall results suggest that Vaeppam pattai kudineer are non toxic to the 
haaematopoietic and leucopoietic system.   The haematopoietic and leucopoietic 
systems are the most sensitive targets for toxic compounds and an important index of 
physiological and pathological status in man and animal (Adeneye, et al., 2006).(13)   
Therefore, it is possible to assume that the Vaeppam pattai kudineer is non 
haematotoxic. 
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ANNEXURE – V 
 
PROFORMA OF CASE SHEET 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
 
PRE CLINICAL AND PHASE II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI  KUDINEER 
 
FORM-I 
(SCREENING AND SELECTION PROFORMA) 
 
1. Name___________ 2. Age_____ 3.Gender________ 4.Phone no _________ 
 
5. OP No/IP No __________  6. S No.__________ 7. Occupation _______ 
 
8. Income __________ 
 
INCLUSION CRITERIA: 
 
• Age : 30 - 60Yrs 
 
• Sex : Both Male and Female 
 
• Patients having symptoms of pain in the low back area, radiating pain to buttocks and lower 
 
limbs 
 
• Stiffness present in the low back area 
 
• Exacerbation of pain on movements 
 
• Pain increased on forward bending ,tingling sensation 
 
• Patients who are willing for admission and stay in IP for minimum 20-30 days or willing to  
 
attend OPD 
 
• Patients who are willing to undergo radiological investigation and give blood and urine  
 
samples for laboratory investigation. 
 
• Patient willing to sign the informed consent stating that he/she will consciously stick to the 
 
treatment during 30 days but can opt out of the trial of his/her own conscious discretion. 
 
• Patients complaining of Back pain functional scale score ranging below 30. 
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EXCLUSION CRITERIA: 
 
 Age below 30 years and above 60 years 
 Diabetes mellitus 
 Auto immune disease like SLE, RA 
 Chronic kidney disease 
 Fracture of spine 
 Tuberculosis of spine 
 Congential spino vertebral deformities 
 Cardiac disease 
 Endocrine disorders 
 Malignancy 
 Systemic hypertension 
 Pregnancy and lactation 
 Osteomyelitis 
 Liver disorder 
 Chronic alcoholic and smokers 
 
 
 
 
 
 
 
 
 
 
Date: 
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Guide :       Signature of the HOD: 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRE CLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS)  
VAEPPAM PATTAI KUDINEER 
 
FORM-l A 
HISTORY PROFORMA ON ENROLLMENT 
 
1. Serial No of the case:   _______________                           2. OP/IP No:_________ 
 
3. Name: ________________     4. Gender:  Male                     Female    
 
5. Age (years): _________   
 
6. Address:  
 
 
 
 
7. a). Occupation:    ---------------------------                         b). Nature of work----------------- 
 
8. Educational  Status:   a). Illiterate                  b). Literate  
 
9. Height: ---------- cms                10. Weight: ----------kg 
 
11. Complaints and Duration:   
________________________________________________________________________ 
 
_______________________________________________________________________ 
 
________________________________________________________________________ 
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12. Past History:                      
 Systemic Hypertension : 
 Diabetes mellitus : 
 Bronchial Asthma :  
 PT   :  
 MCTD   : 
 
13. Habits: 
 
a). Smoking  : 1. Yes  duration ________ years    Number: _____     2. No  
 
b). Alcoholism: 1. Yes  duration ________ years    Quantity: ____ ml 2. No  
 
c). Tobacco chewing:  1. Yes duration ________ years  2.No 
 
d). Betel chewing:  1. Yes duration ________ years        2.No 
 
14. Dietary style: a). Pure vegetarian b.) Non-vegetarian                 
 
15. Drug history: Had the patient been treated before with allopathy drug?  
 
 1). Yes   2). No                                     
 
16. Marital status: 1. Married         2. Unmarried                                                  
 
17. Family history: 
 
      Whether this problem runs in family?             1. Yes                               2.No   
 
       If yes, mention the relationship of affected person(s)  - ___________________________                                                                
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18. Bowel habits & micturition:    Normal  
 
History of habitual constipation              1. Yes                      2. No                                                       
 
History of chronic diarrhoea                  1. Yes                      2. No                                                         
 
History of recurrent UTI                      1. Yes                      2. No                
19. Psychological state:      Normal                    Anxiety                   Depression           
 
 
 
 
 
 
 
 
 
 
 
 
Date :   
Station : 
 
 
 
 
Signature of the Investigator: 
 
 
 
 
 
 
Signature of the Guide:                                                            Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
 
FORM-II & II-A 
CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1.S.No.:  _______   2. OP/IP No.: __________             3.Age: _________ 
4.  Name: _______________________  5. Gender: __________ 
6. Occupation: ______________      7. Date of assessment: _____________  
SIDDHA SYSTEM OF EXAMINATION 
1. ENVAGAI THERVUGAL (EIGHT-FOLD EXAMINATION): 
 I. NAADI (PULSE PERCEPTION): 
 
0st 
Day 
07th 
Day 
15th 
Day 
21st 
Day 
28th 
Day 
30th 
Day 
Vali 
      
Azhal 
      
Iyyam 
      
ValiAzhal 
      
Azhalvali 
      
Iyyavali 
      
ValiIyyam 
      
AzhalIyyam 
      
IyyaAzhal 
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II. NAA (TONGUE): 
 
  0th Day 07th Day  14th Day   21st Day 28th Day 30th Day 
Colour Dark/         
Yellow/ 
Red/       
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Taste Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
III. NIRAM (COLOUR COMPLEXION): 
0th Day 07th day 14th Day 21stDay 28th Day 30th day 
Dark/ 
Yellow/ 
tinted/Pale 
Dark/ 
Yellow/ 
tinted/Pale 
Dark/ 
Yellow/  
tinted/Pale 
Dark/ 
Yellow/ 
tinted /Pale 
Dark/ 
Yellow/ 
tinted/Pale 
Dark/ 
Yellow/ 
tinted/Pale 
 
IV. MOZHI (VOICE):  
0th Day 07th day 14th Day 21stDay 28th Day 30th day 
Medium/ 
High/ 
Low / 
Pitched 
Medium/ 
High/ 
Low/ 
Pitched 
Medium/ 
High/ 
Low/ 
pitched 
Medium/ 
High/ 
Low/ 
pitched 
Medium/ 
High/ 
Low/ pitched 
Medium/ 
High/ 
Low/ pitched 
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V. VIZHI (EYE) (PALPEBRAL CONJUNCTIVA): 
0th Day 07th day 14th Day 21stDay 28th Day 30th day 
Dark/ 
Yellow / 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
 
VI. MALAM (BOWEL HABITS / STOOLS): 
 0th Day 07th Day 14th Day 21stDay 28th Day 30th day 
Colour Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
 Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Consistency Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
VII. URINE EXAMINATION: 
NEER 
KURI 0
th
 Day 07th day 14th Day 21stDay 28th Day 30th Day 
Niram 
(Colour) 
White/ 
Yellowish/ 
Straw 
coloured/ 
Crystal 
clear 
White/ 
Yellowish/
Straw 
Coloured/ 
Crystal 
clear 
White/ 
Yellowish/ 
Straw  
coloured/ 
Crystal 
clear 
White/ 
Yellowish/ 
Straw  
coloured/ 
Crystal 
clear 
White/ 
Yellowish/ 
Straw  
coloured/ 
Crystal 
clear 
White/ 
Yellowish/ 
Straw  
coloured/ 
Crystal 
clear 
Manam 
(Odour) 
Present/  
Absent 
 Present/  
Absent 
Present/  
Absent 
Present/  
Absent 
Present/  
Absent 
Present/  
Absent 
Nurai 
(Froth) 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai 
(Sp. gravity)                              
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/
Reduced 
Normal/ 
Increased/
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
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Enjal 
(Deposits) 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/
Reduced 
Normal/ 
Increased / 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
 
NEI KURI 0
th
 
Day 
7th 
Day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
Serpentine fashion 
      
Annular/Ringed fashion 
      
Pearlbeaded fashion    
      
Mixed fashion 
      
Other fashion 
      
 
VIII. SPARISAM (PERCEPTION): 
 
0th Day 7th day 14th Day 21stDay 28thDay 30th day 
Warmth/ 
Cold/ 
 Sweat 
Warmth/ 
Cold/ 
Sweat 
Warmth/ 
 Cold/ 
Sweat 
Warmth/ 
Cold/ 
Sweat 
Warmth/ 
Cold/ 
Sweat 
Warmth/ 
Cold/  
Sweat 
 
2. THEGI (BODY CONSTITUTION): 
Vatham Thegi  Kapham Thegi  
Pitham Thegi  Kalappu Thegi  
 
3. NILAM (LAND WHERE PATIENT LIVED MOST): 
Kurinji  Mullai   Marutham  Neithal  Palai 
(Hilly terrain)      (Forest range)       (Plains)                   (Coastal)               (Arid regions)  
4. KAALAM: 
Kaarkalam    Pinpanikalam 
Koothirkalam    Ilavenil  
Munpanikalam    Muthuvenil  
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5. GUNAM: 
Sathuva Gunamm                        Raso Gunam                           Thamo Gunam 
6. IMPORIGAL (SENSORY ORGANS): 
 
0th 
Day 
7th 
Day 
14th 
Day 21stDay 
28th 
Day 
30th 
Day 
Mei (Skin)       
Vai (Buccal Cavity)       
Kann (Eye)       
Sevi (Ear)       
Mooku (Nose)       
 
7. KANMENDRIYAM (MOTOR ORGANS): 
 
0th 
Day 
7th 
Day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
Kai (Upper Limb) 
      
Kaal (Lower Limbs )       
Vai (Buccal Cavity)       
Eruvaai (Excretory Organs)       
Karuvaai  (Reproductive Organs)       
 
8. KOSANGAL (SHEATH): 
 
0th 
Day 
7th 
Day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
AnnamayaKosam       
Pranamayakosam       
Manomayakosam       
Vignanamayakosam       
Ananthamayakosam       
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9. MUKKUTRAM (CONDITION OF THREE HUMORS): 
 
a). VATHAM: 
 
0th 
Day 
7th 
Day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
Praanan 
      
Abaanan  
      
Viyaanan 
      
Udhaanan 
      
Samanan 
      
Naagan 
      
Koorman 
      
Kirukaran 
      
Devathathan 
      
Dhananjeyan 
      
 
b). PITHAM: 
 
0th 
Day 
7th 
day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
Anala Pitham        
 Ranjagam       
Saathagam       
Praasagam       
Aalosagam       
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c) KAPHAM: 
 
0th 
Day 
7th 
Day 
14th 
Day 
21stD
ay 
28th 
Day 
30th 
Day 
Avalambagam       
Kilaethagam       
Pothagam       
Tharpagam       
Santhigam       
 
10. SEVEN THATHUS (7 SOMATIC COMPONENTS): 
 
0th 
Day 
7th 
Day 
14th 
Day 
21st
Day 
28th 
Day 
30th 
Day 
Saaram (Chyme)       
Senneer (Blood)       
Oon (Muscle)       
Kozhuppu (Fat)       
Enbu (Bones)       
Moolai (Bone marrow)  
 
    
Sukkilam (Spermatoza) / 
Suronitham (Ovum) 
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11. SYSTEMIC EXAMINATION: 
 
 
0th 
Day 
7th 
Day 
14th 
Day 
21st
Day 
28th
Day 
30th 
Day 
Locomotor system       
Cardiovascular system       
Respiratory system           
Gastro intestinal system       
Central nervous system        
Urogenital system       
Endocrine system       
 
12. GENERAL EXAMINATION: 
 
0th 
Day 
7th
Day 
14th 
Day 
21st
Day 
28th
Day 
30th
Day 
Height (cm)      
 
Weight (kg)      
 
Temperature (F0)         
 
Pulse rate (per min)      
 
Heart rate (per min)      
 
Respiratory rate (per min)      
 
Blood pressure (mm/Hg)      
 
Pallor      
 
Clubbing      
 
Jaundice      
 
Cyanosis      
 
Lymphadenopathy      
 
Jugular vein pulsation      
 
Pedal oedema      
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13. CLINICAL SYMPTOMS: 
 
 
COMPLAINTS 0th Day 7th Day 15th Day 30th Day 
Pain in low back area 
    
Nature of pain 
    
Onset of pain 
    
Radiating pain to buttocks 
    
Radiating pain in right lower limb 
    
Radiating pain in left lower limb 
    
Pain increased on forward bending 
    
Sensory loss on affected area 
    
Numbness 
    
Tenderness 
    
Restriction of movements 
    
Burning sensation in lower extremities 
    
 
 
 
The Back pain function scale (BPFS) of Stratford et al over view 
 
Stratford et al developed the Back Pain Function Scale (BPFS) to evaluate functional  
 
ability in patients with back pain. The authors are from McMaster University  
 
Appalachian Physical Therapy (Georgia) and Virginia Commonwealth University. 
Measures: 
 
(1) Any of your usual work housework or school activities 
 
(2) Your usual hobbies recreational or sporting activities 
 
(3) Performing heavy activities around your home 
 
(4) Bending or stooping 
 
(5) Putting your shoes or socks (or stockings or pantyhose) 
 
(6) Lifting a box of groceries from the floor 
 
(7) Sleeping 
 
(8) Standing for 1 hour 
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(9) Walking 1 mile 
 
(10)Going up or down 2 flights of stairs (about 20 steps) 
 
(11)Sitting for 1 hour 
 
(12)Driving for 1 hour 
 
Responses Points: 
unable to perform activity 0 
 
extreme difficulty1 
 
quite a bit of difficulty 2 
 
moderate difficulty 3 
 
a little bit of difficulty 4 
 
no difficulty 5 
 
Total score = SUM (points for 12 measures) 
 
Adjusted total score = (total score) / 60 Interpretation: 
 
•Minimum score: 0 
 
• Maximum score: 60 
 
• Maximum adjusted score: 1 (100%) 
• The higher the score the greater the patient's functional ability. 
 
Total Score (Adjusted) Interpretation 
 
0 (0%)                 unable to perform any activity 
 
60 (100%)           no difficulty in any activity 
 
References: 
 
Stratford PW Binkley JM et al. Development and initial validation of the Back Pain 
 
Functional Scale.Spine.2000; 25: 2095-2102 (Appendix A page 2101). 
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14. BACK PAIN FUNCTIONAL SCALE SCORE: 
 
SL.NO 
 
PATIENT’SACTIVITIES 
 
NORMAL SCORE PATIENT’S SCORE 
 
1 
Any of your usual work house 
work or school activities 
 
5 
 
 
2 
Your usual hobbies recreational 
or sporting activities 
 
5 
 
 
3 
Performing heavy activities 
around your house 
 
5 
 
4  Bending or stooping 5 
 
5 Putting your shoes or socks 5 
 
 
6 
Lifting a box of groceries from 
the floor 
 
5 
 
7 Sleeping 5 
 
8 Standing for 1 hour 5 
 
9 Walking 1 mile 5 
 
 
10 
Going up or down2 flights of 
stairs (20 steps) 
 
5 
 
11 Sitting for 1 hour 5 
 
12 Driving for 1 hour 5 
 
(Minimum Score- 0, Maximum Score-60) 
 
PAIN SCORE 
 
             BEFORE TREATMENT                 AFTER TREATMENT 
 
  
 
15. CLINICAL EXAMINATION: 
A. INSPECTION: 
 
 0th Day 7th Day 
 
14th Day 
 
21st Day 
 
28th Day 
 
30th Day 
 
         Attitude 
 
      
         Muscle 
 
      
         Wasting 
 
      
         Swelling 
 
      
xxxvii 
 
 
B.PALPATION: 
 
 
 
C.MOVEMENTS: 
 
 
 
Date: 
 
Station: 
 
 
 
Signature of the Investigator: 
 
Signature of the Guide :     Signature of the HOD 
  
 0th Day 7th Day 
 
14th Day 
 
21st Day 
 
28th Day 
 
30th Day 
 
Tenderness 
 
      
Muscle spasm 
 
      
Local heat 
 
      
Local lymphadenopathy 
 
      
Pitting oedema 
 
      
Joint stiffness 
 
      
 0th Day 7th Day 
 
14th Day 
 
21st Day 
 
28th Day 
 
30th Day 
 
Stiffness 
 
      
Restriction of 
movements 
      
Rotation 
 
      
Flexion 
 
      
Extension 
 
      
Lateral bending 
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GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
 DEPARTMENT OF POTHU MARUTHUVAM 
PRE CLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
                         THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
FORM-III 
LABORATORY INVESTIGATIONS 
 
1 Sl. No. 
 
2 OP/IP No  
3 Bed No 
 
4 Name  
5 Age 
 
6 Gender  
I. BLOOD: 
 
Sl. No. Details Before Treatment After Treatment 
1 
 
TC (cells/mm)   
2 
 
DC (%)   
 a) Neutrophils  
 
 
 b) Lymphocytes  
 
 
 c) Monocytes  
 
 
 d) Eosinophils  
 
 
3 
 
ESR(mm)   
 a) 1/2 hour  
 
 
 b) 1 hour  
 
 
4 
 
Haemoglobin   
5 
 
Blood sugar   
6 
 
Blood urea   
7 
 
Serum creatinine   
8 
 
Serum cholesterol   
9 Serum Uric acid   
10 RA Factor   
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II. URINE: 
 
Sl. 
No. Details Before Treatment After Treatment 
1. Albumin   
2. Sugar   
3. Deposit   
 a). Epithelial cells   
 b). Pus cells   
 c). Red blood cells   
 d). Casts/Crystals   
 
III. X-RAY OF THE AFFECTED JOINTS: 
 
Region affected Impression:  Before Treatment 
Impression:  
After Treatment 
 
 
 
 
 
 
 
 
 
 
  
 
 
Date       :       
Station   : 
 
 
Signature of the Investigator: 
 
 
 
Signature of the Guide     :                                          Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH   
VAEPPAM PATTAI KUDINEER 
 
FORM-IV 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all details about the study in the terms readily 
understood by the patient. 
 
Date: ……………..      Signature: …………………………. 
  Name: …………………………….. 
 
CONSENT BY PATIENT 
 
              I have been informed to my satisfaction, by the attending physician, the purpose of 
the clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 
    I am aware of my right to opt out of the trial at any time during the course of the 
trial without having to give the reasons for doing so. 
 
 I, exercising my free power of choice, hereby give my consent to be included As a 
subject in the clinical trial of  VAEPPAM PATTAI KUDINEER for the management of 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS). 
 
Date:      Signature: ………………………………… 
Name: ……………………………………. 
      Signature of Witness: ……………………. 
Name………….. …………………………   
                                                                        Relationship: ……………………………. 
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muRrpj;jkUj;Jtf; fy;Y}hp; ; ; ;; ; ; ;; ; ; ;  kw;Wk; kUj;Jtkid; ; ;; ; ;; ; ;  
 ghisaq;Nfhl;il>; ;; ;; ;  jpUney;Ntypkhtl;lk;.; ; ;; ; ;; ; ;  
gl;lNkw;gbg;G; ; ;; ; ;; ; ;  nghJ kUj;Jtj;Jiw; ;; ;; ;  
jz;lfth;;; jk;;;; Neha;f;F; ;; ;; ;  kUe;jhf;;;  
Ntg;gk;gl;il; ; ;; ; ;; ; ;  FbePHPPP  
ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  Ma;T;;;  xg;Gjy; gbtk;; ; ;; ; ;; ; ; 
 
Ma;thshpd; rhd;wpjo;; ; ; ;; ; ; ;; ; ; ; 
 
 ehd; ,e;j Ma;T Fwpj;J tpguq;fisAk; Nehahspf;Fg; GhpAk; tifapy; 
vLj;Jiuj;Njd; vdcWjpaspf;fpNwd;. 
 
 
 
       ifnahg;gk; 
       ngaH:  
Njjp : 
,lk; : 
 
Nehahspapd; xg;Gjy;; ; ;; ; ;; ; ; 
 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;> kUe;jpd; jd;ikkw;Wk; 
kUj;Jt topKiwiag; gw;wpAk; njhlHe;J vdJ cly; ,af;fj;ij fz;fhzpf;fTk;> 
mjidg; ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l ghpNrhjidfs; gw;wp jpUg;jp 
mspf;Fk; tifapy; Ma;TkUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; chpikia 
njhpe;jpUf;fpNwd;.  
 ehd; vd;Dila Rje;jpukhf NjHT nra;Ak; chpikiaf; nfhz;L 
jz;;;;lfthjk;;;; Neha;f;F kUe;jhf Ntg;gk;gl;il ; ; ;; ; ;; ; ; FbePPPPH ghpfhpg;Gj; jpwidf; 
fz;lwpAk; kUj;Jt Ma;tpw;F vd;id cl;gLj;j xg;Gjy; mspf;fpNwd;. 
 
Njjp :                                                     ifnahg;gk; 
,lk; :      ngaH:  
 
       rhl;rpapd; ifnahg;gk; 
       ngaH: 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRE CLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
 
FORM- IV A 
WITHDRAWAL FORM 
 
 
Name: ________________________       OPD/ IPD number: __________ 
Age   : ________     Gender: ______    Occupation: ___________________ 
Date of trial commencement: ___________ 
Date of withdrawal from trial: ___________ 
Reasons for withdrawal: 
• Long absence at reporting   :  Yes                No 
• Irregular treatment    : Yes                 No 
• Shift of locality    : Yes                 No 
• Increase in severity of symptoms  : Yes                 No 
• Development of severe adverse drug reactions: Yes                 No 
Date : 
Station :     
 
 
Signature of Investigator     Signature of HOD 
 
 
 
 
Signature of Guide 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE-II RANDOMIZED OPEN LABELLED 
CLINICAL STUDY ON THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
 
FORM-IV B 
 
PATIENT INFORMATION SHEET 
 
• It is a degenerative disc disease. 
• This disease is not contagious. 
• It primarily affects jointsand typically results in low back pain, radiating pain to lower 
limbs andstiffness. 
• Many herbal and mineral siddha medicines are currently practiced by the siddha 
practitioners for this disease. 
• The trial drug is prescribed only with the evidence of Siddha literature. 
• The trial drug is prepared at the Gunapadam Lab of Government Siddha Medical 
College & Hospital, Palayamkottai under the direct supervision of teaching faculties 
of PothuMaruthuvam and Gunapadam Department. 
 
Details of the trial drug: 
Drug  : VAEPPAM PATTAI  KUDINEER 
Dose  : 50 ml twice a day. 
Duration : 30 days.   
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murpdH rpj;jkUj;Jtf; fy;Y}hp; ; ; ;; ; ; ;; ; ; ;  kw;Wk; kUj;Jtkid ; ; ;; ; ;; ; ;
ghisaq;Nfhl;il>jpUney;Ntypkhtl;lk;.; ; ; ; ;; ; ; ; ;; ; ; ; ;  
gl;lNkw;gbg;G; ; ;; ; ;; ; ;  nghJ kUj;Jtj;Jiw; ;; ;; ;  
Ntg;gk;gl;il; ; ;; ; ;; ; ;  FbePPPPhpd; ghpfhpg;Gj; jpwidf; ; ; ; ;; ; ; ;; ; ; ;  
fz;lwpAk; ; ;; ;; ; kUj;JtMa;Tjfty; gbtk;; ; ; ;; ; ; ;; ; ; ; 
 
• jz;lfthj NehahdJ KJF vd;G Nja;khdj;jhy; Vw;glf;$ba NehahFk;. 
• ,e;Nehapy; KJFvd;gpy; typ> typahdJ ,U fhy;fSf;F guty;> tpiwg;G 
jd;ik Mfpad fhzg;gLk;. 
• rpj;jkUj;Jtj;jpy; mjpfmsT %ypiffs; kw;Wk; jhJg; nghUl;fs; 
,e;Neha;f;F kUe;jhfg; gad;gLfpwJ. 
• Vw;fdNt cgNahfj;jpy; cs;s ,J Nghd;w kUe;Jfs; ,Jtiu 
Nehahspfsplk; ve;jtpj gf;ftpisTfis Vw;gLj;jtpy;iy.  
• ,e;j kUe;J rpwg;ghf jz;lfthjk; Neha;f;fhfmq;fPfhpf;fg;gl;l rpj;jkUj;Jt 
E}ypy; ngwg;gl;Ls;sJ. 
• Nkw;fz;l kUe;jhdJ murpdH rpj;jkUj;Jtf; fy;Y}hp kw;Wk; kUj;Jtkid> 
ghisaq;Nfhl;ilapy; cs;s gl;l Nkw;gbg;G Fzg;ghlk; kUe;J nra; 
Ma;tfj;jpy;  nra;J Kbf;fg;gl;lJ. 
• ,e;j Muha;r;rp rk;ge;jkhf rpy Nfs;tpfisf; Nfl;fTk;> Njitahd Ma;tf 
ghpNrhjidf;Fj; jq;fis cl;gLj;jTk;  cs;Nsd;.  
• ,J rk;ge;jkhf jq;fsJ midj;J tpguq;fSk; ufrpakhf itf;fg;gLk; 
vd;W cWjpaspf;fpNwd;. 
• ,e;j Muha;r;rpapd; NghJ clYf;F NtW ghjpg;G Vw;gLk; gl;rj;jpy; murpdH 
rpj;jkUj;Jtf; fy;Y}hp kw;Wk; kUj;Jtkid> ghisaq;Nfhl;ilapy; jf;f 
rpfpr;ir mspf;fg;gLk;. 
• ,e;j Muha;r;rpapy; NrHe;j gpwF cq;fSf;F tpUg;gk; ,y;iynadpy; 
vg;nghOJ Ntz;LkhdhYk; tpyfpnfhs;syhk;. 
NkYk;  ,e;j Muha;r;rpf;F IEC mDkjpr; rhd;W ngwg;gl;Ls;sJ.  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRE CLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
 
FORM–IV C 
 
ADVERSE DRUG REACTION FORM 
 
 
 
Name: ________________________       OPD/ IPD No: __________ 
Age: ________     Gender: ____  Occupation: ____________________ 
Date of trial commencement: ___________ 
Date of withdrawal from trial: ___________ 
Description of adverse reaction: 
____________________________________________________________________ 
____________________________________________________________________ 
 
Date : 
Station :     
 
 
 
 
 
Signature of Investigator     Signature of HOD 
 
 
 
 
 
 
Signature of  Guide 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
DISCHARGE CASE SHEET PROFORMA FOR 
“THANDAGA VATHAM (LUMBAR SPONDYLOSIS)” 
 
FORM-IV D 
 
I.P. No.  :   Occupation   :  
Bed No.  :   Income   :  
Ward No.  :   Nationality   :  
Name    :   Religion   :  
Age / Sex  :   Date of Admission :  
Address  :   Date of Discharge :  
Diagnosis  :  
No. of Days treated :  
 
 
 
 
 
 
 
CLINICAL PROGNOSIS: 
 
 
 
 
AT THE TIME OF 
ADMISSION 
AT THE TIME OF 
DISCHARGE 
  
 
 
 
 
 
 
Medical Officer Signature:  
PROF / H.O.D  
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRE CLINICAL AND PHASE-II RANDOMIZED CLINICAL TRIAL ON 
THANDAGA VATHAM (LUMBAR SPONDYLOSIS) WITH 
VAEPPAM PATTAI KUDINEER 
 
 
FORM-IV E 
(DRUG COMPLIANCE FORM) 
 
 
Name of The Drug : VAEPPAM PATTAI KUDINEER 
Drugs issued date :  
Drugs returned date : 
Days DATE 
DRUG TAKEN TIME 
MORNING TIME EVENING TIME 
Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
Day 8    
Day 9    
Day 10    
Day 11    
Day 12    
Day 13    
           Name : _____________________ Age/ Sex : ___________     S. No : _________ 
          OPD/ IPD No : ____________ Date       : ___________   Bed No : _________  
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Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 20    
Day 21    
Day 22    
Day 23    
Day 24    
Day 25    
Day 26    
Day 27    
Day 28    
Day 29    
Day 30    
 
 
 
 
 
 
Date : 
Station :     
 
 
 
 
 
Signature of Investigator     Signature of HOD 
 
 
 
 
 
 
Signature of  Guide 
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Abstract
Aim: The aim of the study   is to examine  the sample drug Mathiiushna Rasayanam  through  Microbial Limit
Testing( Microbial Contamination Test, Specific Pathogen Testand the  screening of   antimicrobial  activity  by agar
well diffusion method).
Methodology: Mathiiushna Rasayanam was prepared  as per Siddha Materia Medica procedures.Extract of test
sample Mathiiushna Rasayanam was prepared. Microbial Limit Testing-Total bacterial counting , total fungal
counting and the  screening of   antimicrobial  activity  by agar well diffusion method were done.
Result: Thus the present study shows that Mathiiushna Rasayanam is free from   microbial contamination. Both
Gram positive and Gram negative bacteria were found to be high sensitive to Mathiiushna Rasayanam when
compared to the standard drug Gentamycin (Broad spectrum).
Conclusion: It is concluded that the test drug Mathiiushna Rasayanam can be prescribed as the medicine for
infectious disease due to pathogenic micro organism namely, Escherichia coli, Klebsiella pneumoniae, Salmonella
typhi, Pseudomonas aeuroginosa and Staphylococcus aureus infections. This study also reveals that the Siddha
literature evidence which was mentioned thousands years before the advent of modern science by Siddhars in
Yuukivaithiyakaaviyum becomes true to this modern era.
Keywords: Siddha, Mathiiushna Rasayanam, Microbiological examination.
Introduction
The Siddha medicine is one of the oldest medical
systems known to mankind. The word Siddha
comes from the word Siddhi which means an
object to be attained perfection or heavenly bliss.
Siddha is focused to “Ashtamahasiddhi” that is
the eight supernatural powers. Those who attained
or achieved the “Ashtamahasiddhi” powers are
known as Siddhars. Siddha medicine is claimed to
revitalize and rejuvenate dysfunctional organs.
The Siddha medicine given by practitioners
includes leaves, flowers, fruit and various roots in
a mixed basis.
Infectious disease, also known as transmissible
disease or communicable disease is illness
resulting from an pathogenic microbial infection.
Dating back to Ancient Siddha literature, the
Siddha formulations were found to be highly
effective in prevention of the infectious diseases.
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ABSTRACT: 
A tremendous interest exists in global herbals and herbal based medicine is rapidly increasing 
commercial and scientific value. Till now,the concept of herbal combination is appreciated 
with its superior efficacy and lesser side effects in comparison with either single isolated 
constituents of herbal.The greater interaction between traditional systems of medicine with 
modern tools has opened up the possibility to insight antimicrobial activities of herbal 
preparations . Target Anti bacterial herbal drug selection plays a vital role and considered to 
be a heart of the new siddha drug discovery . In a great majority of  cases, bacterial species  
are considered to be  the most commonly isolated  organisms   . Dating back to Siddha 
literature, “Siddha materia medica” indicates  Kodupaai herbal preparations  for preventing 
Respiratory disorders. In this article, an attempt has been made to highlight the indepth 
scientific value and antibacterial sensitivity testing of the Siddha drug Kodupaai chooranam 
,to ensure  quality health. 
Key words: Siddha, Kodupaai chooranam, Respiratory disorders, Antibacterial sensitivity. 
Introduction: 
The emergence of new infectious diseases, the resurgence of several infections that appeared 
to have been controlled and the increase in bacterial resistance have created the necessity for 
studies directed towards the development of new antimicrobials. In recent times, the search 
for potent antibacterial agents has been shifted to herbals. The anti microbial efficacy value  
attributed to some herbals is beyond belief. Therefore, there is a need to develop alternative 
antimicrobial drugs for the treatment of  infectious diseases .As a result herbals are still 
recognised as the bedrock for the modern medicine to treat infectious diseases. 
 
 
 
